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Preface 
In his book Tumeurs Humaines published in French in 1956 and translated to English in 1970 
(Human Tumors) (1), the French Canadian pathologist Pierre Masson made the statement: 
“No classification is more difficult to establish than that of thyroid epitheliomas…………, very 
few are adapted to a precise classification”. In 1964, In The New England Journal of 
Medicine, Veith and co-workers presented the paper “The Nodular Thyroid Gland and 
Cancer- A Practical Approach to the Problem” in which the following statements was made: 
“Unlike most other tumors, thyroid cancer has an unusually broad spectrum of behaviour. At 
one extreme is the well differentiated, slow-growing process that behaves in an almost benign 
manner. At the other extreme is the poorly differentiated, rapidly fatal anaplastic process. 
Knowledge of the broad zone between these two extremes is limited…..” (2). These 
statements, written 60-70 years ago, are still elucidating our present situation interest. Until 
the 1990ties, differentiated thyroid carcinomas were principally divided in the two main 
categories: Follicular and Papillary. Further sub classification of thyroid tumors was of 
limited interest. However, during the last two decades, several publications have described 
different variants of thyroid neoplasias. The different morphological subtypes turn out to 
demonstrate distinct biologic behaviours at onset and during follow-up and additionally 
different overall survival. Thus, sub classification of these tumors is urgent for the clinicians, 
and our improved understanding of molecular mechanisms for development also allows future 
targeted therapy. 
 
Most of the lesions disclosed in the thyroid gland are benign. The fact that the number of 
thyroid lesions examined are steadily raising due to a more extensive use of radiological 
devices with constantly improved resolution has become a significant challenge. Not only 
have the effort to find markers capable of separating benign and malignant lesions in 
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preoperative specimens exploded, but the need for a multidisciplinary approach has become a 
prerequisite for optimal patient treatment.  
 
As a cytopathologist and surgical pathologist with a special interest in the pathology of the 
thyroid gland, I have for years performed on-site evaluation of the fine needle aspirations 
(FNAB) as well as assessment of thyroid histological specimens. The on-site evaluation 
includes clinical cooperation in collecting the patient’s anamnestic data and carrying out the 
cytological specimen. This subspecialisation as well as regular meetings in a multidisciplinary 
team guarantees a high quality diagnostics and treatment and have in our hospital acted as an 
arena for development of collaborative projects. Being a member of a multidisciplinary team 
for several years, I have been involved in several steps of the management of patients with 
thyroid lesions, including speaking to the patients to obtain valuable anamnestic information. 
Additionally, I have performed the FNAB, watched US-imaging and listened to the 
radiologist interpretation. In the last years I have also had the opportunity to integrate the 
interpretation of the thyroid specimens with electronically accessible information from 
medical reports, laboratory data, flow-cytometry, genetic studies and multiple knowledge 
databases. But not at least, I have had the pleasure to work closely together with dedicated 
physicians from a wide range of specialities and my thesis is an unreservedly product of this 
multidisciplinary collaboration. 
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Introduction 
An insignificant thyroid lesion is a frequent finding on US examination, particularly in 
women. Up to 72% of adult women were found to have at least 1 thyroid nodule (3). Only 4% 
to 5% of thyroid nodules are malignant according to histopathological examination (4;5). 
Fine-needle aspiration (FNAB) has been accepted as a first-line screening test for patients 
with thyroid nodules and is also widely used for examination of lymph nodes in the neck. 
FNAB is a safe and cost effective diagnostic procedure with accuracy in distinguishing 
between benign and malignant thyroid nodules approaching 94% (6). The major limits of this 
procedure are the high rate of inadequate specimens (7-9) and the fact that FNAB cannot 
distinguish between benign and malignant follicular lesions due to identical cytomorphology 
(10). Clinical examination, ultrasonography and cytological examinations are all subjective 
methods with diagnostic limitations. Thus, it is a supposition that both the radiologist 
performing the ultrasonography and the cytopathologist doing on-site FNAB evaluation are 
dedicated and experienced. A multidisciplinary approach with experienced physicians can 
ensure an optimal diagnostic accuracy, as also shown in Paper I.  
 
On-site evaluation of the FNAB specimens implies that a cytopathologist/cytotechnician 
participate when the FNAB is performed and immediately, at the out patient clinic, evaluate 
the smears. This on-site approach not only guarantees specimen adequacy, but will also aid 
the FNAB operator to achieve additional material for ancillary analysis. Examination of 
FNAB wash-out specimens may identify thyroglobulin (Tg). The present work describes how 
this technique may aid the clinician in diagnosing neck lymph node metastases (Paper II). 
Repeated neck explorations with the aim to eradicate lymph node metastases from papillary 
thyroid carcinoma PTC in patients with a previous thyroidectomy may be a challenge due to 
scar formation and also involves a greater risk of permanent recurrent laryngeal nerve 
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paralysis. When doing US-guided FNAB on neck lymph nodes on these patients, an instant 
diagnosis of malignancy might enable the radiologist to perform percutaneous ethanol 
injection with the aim to cure lymph node metastases, described in Paper III.  
 
Classical PTC is easily diagnosed on cytological smears as well as clearly metastatic cells in 
smears from cervical lymph nodes. In contrast to PTC, follicular carcinomas (FTC) are 
usually more challenging and difficult or impossible to diagnose. When a FNAB indicates 
follicular neoplasia, malignancy cannot be excluded. Some of these specimens may be 
considered to be benign, causing a delay in diagnosing FTC. The higher prevalence of large 
FTC with distant metastases and hence poorer survival rates than PTC patients can be 
attributed to the delay in diagnosing (11;12). 
 
In the light of our improved understanding of molecular biology significant research efforts 
have been performed to identify gene expression profiles that may predict malignancy 
(13;14). However, although gene expression profiling studies have identified many possible 
biomarkers, the clinical application is not settled, and multicenter validation trials have to be 
performed to evaluate the accuracy. The disappointing results achieved when we attempted to 
validate four emerging biomarkers suggestive of differentiating FTA from FTC are presented 
in Paper IV. The role of the pathologist in management of thyroid cancer patients is changing. 
Figure 1 illustrates how the studies like the four included in this thesis may support the 
decision making.  
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Figure 1. Modified from J. Sinard (15): The different aspects of thyroid diagnostics are visualized and the crucial 
position the pathologist may have making diagnoses on specimens from thyroid- and thyroid related neck 
lesions. The four publications in this thesis arose as a consequense of the challenges we have met making thyroid 
diagnoses, but also, as being member of the multidiciplinary team, I realized the challenges we have been facing 
in treatment of thyroid carcinoma patients.  
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Background 
Incidence 
Clinically palpable thyroid nodules are found in 4% to 10% of the adult population in the 
United States and 1 of 20 clinically identified nodules is malignant (4;16). By ultrasound 
examination thyroid nodules are found in 20% to 72% (3;17). By autopsy thyroid nodules are 
detected in approximately 50% of the glands (18;19). Prevalence is dependent on age, 
exposure to ionizing radiation, and iodine deficiency. Thyroid nodules are more frequent in 
women than in men.  
 
According to WHO (20), the age standardized incidence rates per 100,000 population of 
thyroid carcinoma vary from 0.8 to 5.0 for males and 1.9 to 19.4 for females in different parts 
of the world. The highest rates have been reported from Hawaii and Iceland (WHO), whereas 
relatively low incidence rates have been observed in Denmark, the Netherlands and Slovakia. 
In the United States the lifetime risk of developing thyroid cancer is about 1:104 for men and 
women (21). In their study of 1985 patients Frates et al (22) detected a total of 3483 nodules 
larger than 10 mm in maximum diameter, and they found the thyroid cancer occurrence to be 
independent of the number of thyroid nodules. Thyroid carcinoma is the most frequent 
endocrine cancer but still less than 1% of human malignant neoplasms. In Europe, 200,000 
patients have been treated for DTC and are survivors. The incidence of thyroid cancer in 
Norway is approximately two and five per 100,000 for males and females respectively (23). 
An estimated population of 4200 are DTC patients and survivors. The incidence of thyroid 
cancer has increased by 50% in the United States during the past 25 years, probably because 
of incidental findings of small, subclinical PTCs by neck ultrasound for nonthyroid 
indications, extensive used of FNAB, greater exposure to radiation after the Chernobyl 
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accident and also associated with increased use of computed tomography scanning (24;25). A 
similar trend has been observed worldwide. The increased incidence of thyroid cancer in the 
United States is mainly assumed to be due to detection of small PTC and with no significant 
change in the incidence of FTC and MTC.  
 
Risk factors 
The development of the different subgroups of thyroid cancers is influenced by 
environmental, genetic and hormonal factors and in some cases by the interaction among 
them. 
 
Among the environmental factors, ionizing radiation is the best-established cause of thyroid 
carcinoma. Based on five cohorts and two case-control studies Ron et al (26) found in a 
pooled-analysis on this issue with 58000 exposed individuals, 61000 unexposed, 700 thyroid 
carcinoma, and 3 million person-years, a significant dose-risk for exposure during childhood. 
PTCs have been shown to comprise up to 97% of the cancers occuring among atomic bomb 
survivors (26). After the Chernobyl nuclear power plant accident in 1986, there was reported a 
large increase in the incidence of childhood thyroid carcinoma in the contaminated areas (27). 
The risk of radiation-related thyroid carcinoma was shown to be 3-fold higher in iodine-
deficient areas than elsewhere in a population-based study of thyroid carcinoma in Belarus 
and The Russian Federation (28). 
 
Familial factors are extensive in the development of PTC (29). Somatic rearrangements of the 
RET proto-oncogene (30) and BRAF V600E mutations (31;32) are the most common events 
in PTC with BRAF mutation occurring in approximately 45% and RET/PTC is found in about 
35% of adult sporadic papillary carcinomas. FTC is characterised by RAS mutations found in 
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40-50% of conventional FTC and PAX8/PPAR rearrangement in approximately 35% of 
conventional FTC (33). PAX/PPAR tends to occur in tumors present at a younger age, in 
tumors of a smaller size, and also more frequently with vascular invasion. FTC occurs in up to 
10% of patients with Cowden syndrome/PTEN-hamartoma tumor syndrome (34) and a few of 
these patients have also been found to have PTC (35).  
 
In contrast to activation by chromosomal rearrangement in PTC, RET is activated by point 
mutation in MTC. Somatic mutations of the RET gene can be found in 20-80% of patients 
with sporadic MTC whereas germline mutations in specific functional regions of RET are 
found in almost all patients with familial forms of MTC (36). 
 
In women the risk for thyroid carcinoma is approximately 3-fold compared to men. An effect 
of estrogen and /or other factors associated with pregnancy have been suggested, as the 
incidence of thyroid cancer is almost the same for both genders before puberty and after the 
female menopause (37). 
 
Rudolf Virchow was the first to describe a tumor-promoting effect of chronic irritation or 
inflammation (38). Inflammatory cytokines, over expressed by tumor cells, recruit 
haematopoietic cells such as lymphocytes, monocytes, and neutrophils into the vicinity of the 
tumor. Colony stimulating factors, main growth factor for i.e. monocytes, have been shown to 
be over expressed in different tumors (39), and these growth factors were also observed to 
contribute to angiogenesis. Neutrophils and mast cells both contribute to angiogenesis and 
remodelling of extracellular matrix (40;41). Leukocytes express several angiogenic growth 
factors including vascular endothelial growth factor (VEGF) (42), and VEGF ligands bind to 
their cognate receptors and induce proliferation of endothelial and/or lymphatic cells. 
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Increased expression of VEGFs has been reported in thyroid carcinomas (43;44). Thyroid 
tumors have also been shown to over express epidermal growth factor receptors (EGFRs) and 
ligands, implicating EGFR signalling in thyroid tumorigenesis (45;46).The relationship 
between PTC and chronic lymphocytic thyroiditis (i.e. Hashimoto thyroiditis) has long been 
debated. The majority of recent studies have suggested that there is an increased risk of PTC 
in chronic lymphocytic thyroiditis (47). 
 
Goiter and adenomas have been shown to be a major risk factor for thyroid carcinoma. 
According to a pooled-analysis of all case-control studies conducted before 1998, a relative 
risk of 30 was found in patients with a history of benign nodules/adenomas compared to 6 in 
women who had a history of goiter (48). The two main chromosomal patterns observed in 
FTC are shared with FTA, supporting the hypothesis that some adenomas may give rise to 
FTC through additional mutational events (49). In a study of 294 patients with multinodular 
goiter and thyroids surgically removed, the incidence of malignancy was almost 11% (50), 
which is double the incidence of thyroid cancer in the normal population.  
 
Chronic iodine deficiency is known to be a risk factor for goiter and FTC (37;51;52). Iodine 
supplementation programs, on the other hand, inducing iodine excess might, according to 
some epidemiological studies, increase the incidence of PTC (53-55). However, when the 
effects of supplementation are registered, the diagnostic improvements will follow, meaning 
that the increase in incidence probably is due to diagnostic improvement, and not biological 
factors (54;56). 
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The metastatic/infiltrating process 
Extracellular environment and thyroid carcinogenesis/tumorigenesis 
Steven Paget’s seed and soil hypothesis dates back to 1889, and still holds forth today (57). 
He made the proposal that metastasis depends on cross-talk between selected cancer cells (the 
“seed”) and specific organ microenvironments (the “soil”). 
 
Epithelial-stromal interaction is playing a critical role not only for normal organogenesis but 
also for carcinogenesis, and the interaction between cancer cells and their microenvironment 
can largely determine the phenotype of the tumor (58-60). In a review by Chaffer et al (61) 
this statement was made: “From a therapeutic standpoint, understanding the mechanisms 
involved in physical translocation of a cancer cell from primary tumor to the 
microenvironment of distant tissues is likely to be important for preventing metastasis in 
patients who are diagnosed with early cancer lesions, whereas understanding the mechanisms 
leading to successful colonization may lead to effective therapies for patients with already-
established metastases”. Both regulations of transmembrane receptors and of extracellular 
matrix have an influence on cell behaviour affecting viability, proliferation, adhesion, and 
motility. Tumor progression is made possible through the alteration induced by the cancer 
cells on the adjacent stroma to form a permissive and supportive environment (desmoplasia). 
Angiogenesis is also involved in formation of the desmoplasia (62). 
  
Tumor stroma consists of a framework of extracellular matrix as well as fibroblasts, immune 
and inflammatory cells, fat cells and blood-vessel cells. Cancer cells may produce stroma-
modulating growth factors (figure 2) like fibroblast growth factors, ß-catenin, endothelial 
growth factor (VEGF), platelet-derived growth factor, epidermal growth factor receptor 
(EGFR) ligands, interleukins, colony-stimulating factors and transforming growth factor-ß 
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(TGFß) (58). These and other factors activate surrounding stromal cell types like fibroblasts, 
smooth-muscle cells and adipocytes. Activated fibroblasts promote tumor progression by 
secreting growth factors and pro-migratory extracellular-matrix components (58). In this 
epithelial-mesenchymal transition (EMT) process epithelial cells can convert into 
mesenchymal cells (figure 2). A series of events occur in EMT. Epithelial cells lose many of 
their epithelial characteristics and take properties that are typical of mesenchymal cells. 
Complex changes in cell architecture and behaviour are required. The molecular mechanisms 
regulating EMT are considerably overlapping with those that control cell adhesion, motility 
invasion, survival and differentiation (63). EMT is induced by interplay of extracellular 
signals, including components of the extracellular matrix, and also of soluble growth factors 
(members of the TGFß, fibroblast growth factor-FGF and epidermal growth factor-EGF). 
EMT has a central role in tumor progression (64;65). The carcinoma cells acquire 
mesenchymal gene-expression patterns and properties during progression to metastatic 
competence. With changes in adhesive properties, activation of proteolysis, and motility, 
which allowing the tumor cells to metastasize and establish secondary tumors at distant sites 
(66). Vasko and co workers (67) have shown that an expression profile consistent with EMT 
is common in PTC invasion.  
 
Loss of cell-cell contact promotes tumor invasiveness. E-cadherin is a transmembranous 
calcium-dependent cell-cell adhesion molecule, which is highly expressed in benign thyroid 
tissue. The expression of E-cadherin have been shown to be low or absent in widely invasive, 
recurrent or metastatic thyroid carcinomas, whereas the expression in some well-differentiated 
thyroid carcinomas, including minimally invasive lesions is maintained (68;69). Liu et al (70) 
found that the expression of E-cadherin was decreased in the cell membrane of the tumor cells 
with loss of cellular polarity/cohesiveness in the invasive front of papillary thyroid carcinoma. 
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In their study a group of PTCs with loss of cellular polarity/cohesiveness had extra thyroid 
invasion and lymph node metastases more frequently than a group without loss of cellular 
polarity/cohesiveness. The loss of cellular polarity/cohesiveness (LOP/C) resulted in a high 
recurrence risk of PTC. These results are in line with the observations made by Bai and co-
workers (71) in a study demonstrating a significant correlation between the loss of cellular 
polarity/cohesiveness in the invasive front and the up-regulation of the extracellular matrix 
protein, periostin, in tumors. Both of them significantly correlated with extra thyroid invasion, 
pT and lymph node metastasis.  
 
Low-density lipoprotein receptor-related protein (LRP1B) is among the 10 most significantly 
deleted genes across 3312 human cancer specimens. H Prazeres et al (72) recently showed 
that LRP1B is a key tumor suppressor through constraining the abundance of critical members 
of proteolytic systems in the tumor microenvironment. Inactivation of LRP1B was shown to 
result in changes to the tumor environment that conferred thyroid cancer cells and increased 
growth and invasive capacity. Restoration of inactivated LRP1B impaired tumor growth, 
inhibited cell invasion and led to a reduction of matrix metalloproteinase-2 (MMP-2) in the 
extracellular medium. 
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Figure 2. A malignant epithelial tumor is situated in the left lobe and isthmus of the thyroid gland. Some of the 
tumor cells are undergoing a transition thus acquiring properties of mesenchymal cells. These cells are able to 
invade vessels and become metastatic foci. The extracellular matrix is modified both by growth factors and 
proteases produced by the tumor and the activated fibroblasts, and inflammatory cells in the stromal surrounding 
secret additional growth factors and proteases. E-cadherin belongs to a family of single-transmembrane calcium- 
dependent cell-cell adhesion proteins. E-cadherin is highly expressed in normal thyroid, benign adenomas and is 
also maintained in some well-differentiated thyroid carcinomas. E-cadherin is low or absent in recurrent or 
metastatic, and widely invasive thyroid carcinomas (68;69). 
 
 
PTCs have a propensity for intrathyroidal spread via lymphatic vessels with further 
lymphagenous metastases to the regional lymph nodes, whereas FTCs metastasize mainly 
hematogenously. The mechanisms involved are not fully understood. Lympangiogenic growth 
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factors have been shown to be significantly increased solely in PTC, whereas the expression 
of different factors promoting de novo blood vessel formation (hemangiogensis) is increased 
in all thyroid tumors (73-76). 
 
Types of thyroid malignancies and classification 
Table 1. Histopathology classification of malignancies of the thyroid gland according to 
WHO (20) 
 
 
Thyroid carcinomas Other malignant thyroid 
neoplasms 
Papillary  Primary lymphoma and 
plasmacytoma 
Follicular Angiosarcoma 
Poorly differentiated Secondary tumours 
Undifferentiated  
Squamous cell  
Mucoepidermoid  
Sclerosing mucoepidermoid carcinoma with 
eosinophilia 
 
Mucinous  
Medullary  
Mixed medullary and follicular cell  
Carcinoma showing thymus-like differentiation  
  
 
 
The histopathology classification of malignancies of the thyroid gland according to WHO is 
shown in Table 1. In humans, most thyroid carcinomas arise from glandular epithelium (20) 
and up to 95% of tumors are well-differentiated PTCs, FTCs or MTCs, less than 5% of 
carcinomas are undifferentiated (anaplastic). PTC represents approximately 80% of the well-
differentiated carcinomas, FTC 10-15%, and approximately 5% of tumors are MTC. MTCs 
originate from the thyroid C cell that secretes calcitonin. FTC is distinguished from adenoma 
only by recognition of invasion or metastasis. FTCs are divided into groups reflecting the 
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biology of tumor growth and metastasis. Widely invasive FTCs, which are usually identifiable 
as invasive grossly, have a poor prognosis with a 25-45% 10-year survival. Patients with FTC 
with minimal capsular invasion have an excellent prognosis with 10-year survival rates of 70-
100% (77). Survival is better in women and in patients younger than 40 years (78). 
 
Approximately five percent of malignant tumors are lymphomas and metastases (20). 
Metastases to the thyroid gland most frequently arise from malignant tumors in kidney, lung 
and skin (malignant melanoma) (20). In Alpine regions (Switzerland) angiosarcoma has been 
reported to represent approximately 4% of all thyroid malignancies during 1962-1973 (20). 
Endemic goiter associated with iodine-deficiency has been considered a predisposing factor 
(79). Angiosarcoma is extremely rare in other areas with only sporadic cases being reported 
(80-82). 
 
Oncocytic change is defined as cellular enlargement characterised by an abundant 
eosinophilic granular cytoplasm as a result of the accumulation of altered mitochondria. 
The identification of oncocytic change in thyroid tumors has led to major controversies. Some 
lesions that were called benign developed metastases, and therefore some physicians proposed 
that all oncocytic tumors of the thyroid gland should be treated as malignancies (83). 
However, numerous studies have indicated that the criteria that apply to follicular tumors of 
the thyroid also distinguish malignant from benign Hürtle cell lesions (84). 
 
Tall cell, columnar cell, diffuse sclerosing, solid/trabecular, and insular variants of PTC are all 
potentially more aggressive than conventional PTC varieties (85). Akslen and LiVolsi (86) 
found, however, that although histologic variants seemed to be significant factors on 
univariate survival analysis, only greatest tumor dimension and histologic grade remained as 
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independent and significant predictors of carcinoma deaths. Histologic category (ie. tall cell) 
was found to have no independent impact on patient survival. Features recognized by other 
staging systems associated with unfavourable prognosis are also found present in aggressive 
variants of PTC, including presence of distant metastases, extracapsular spread, higher 
histologic grade and large tumor size. Prognosis has been found to be directly related to these 
factors (85). 
 
Papillary thyroid microcarcinoma is defined as any focus measuring 1 cm (87). The clinical 
management of papillary thyroid microcarcinoma is controversial (88;89). Although all are 
clinically indolent tumors that pose little or no risk to the patient’s survival and require little 
or no therapy, some of these patients have recurrences and other adverse outcomes that may 
be difficult to foresee when the diagnosis is first made.   
 
The evaluation of thyroid nodules and neck lymph nodes 
According to European consensus for the management of patients with differentiated thyroid 
carcinoma of the follicular epithelium (90) thyroid ultrasound (US) is the most accurate 
imaging detection technique. In addition to accurately describing the size and character of the 
nodule, US guidance is of crucial importance when performing fine needle aspiration biopsy 
(FNAB) (90). Furthermore, when a malignant diagnosis is made, US evaluation of neck 
lymph nodes is mandatory in the preoperative staging, and US-guided FNAB of 
sonographically suspicious lymph nodes should be performed to confirm malignancy (91). 
 
The Bethesda System for Reporting Thyroid Cytopathology (92) is widely in use. The 
morphological criteria for clearly benign and malignant thyroid lesions are easy to interpret 
and the report from the cytopathologist is easy to comprehend for the clinicians. In contrast, 
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smears from follicular lesions are difficult to diagnose, due to the fact that only capsular 
and/or vascular invasion, detected only by histologic evaluation, can distinguish between FTA 
and FTC, and additionally the diagnosis of follicular variant of PTC may also be challenging 
to distinguish due to the subtlety of diagnostic nuclear features. In the Bethesda System these 
lesions are reported as “Follicular lesions of undetermined significance”. On-site adequacy 
assessment reduces the number of inadequate samples (93-96). The on-site evaluation also 
allows the cytopathologist to achieve important clinical information and is a prerequisite for 
the multimodal approach.  
 
Patients with PTC present with cervical lymph node metastases at the time of primary 
diagnosis in 20-90% of the cases, and more frequently than other histotypes (97). In 10-26% 
of all patients with well-differentiated thyroid carcinoma, cervical lymph node metastases 
present as the first sign of disease (98). According to the “European consensus for the 
management of patients with differentiated thyroid carcinoma of the follicular epithelium” 
(90) a thorough examination of the neck lymph nodes should be performed as part of a 
preoperative staging, and FNAB should be performed in cases where the lymph node presents 
as suspicious on ultrasound. In the follow-up of patients after treatment for thyroid carcinoma 
all suspicious neck lesions should be punctured for cytological examination. The cytological 
specimen from lymph node metastasis is in some cases sparse and suboptimal, as for many 
cystic lesions, and Tg measurement of wash-out FNAB needle specimen, might increase the 
sensitivity (99). 
 
 28
Diagnostic markers for discriminating benign and malignant tumors 
Immunochemical markers  
Diagnostic immunohistochemical thyroid markers were introduced through the study of 
keratin and thyroglobulin in the early 1980ties (100). Since then, studies have been performed 
with the aim to identify new markers to distinguish benign from malignant thyroid tumors. 
Among these markers are CK 19, GAL3 and HBME1. Potentially new markers have also 
been tested on cytological specimens. Some studies have included specimens categorized as 
suspicious for follicular neoplasia, in which overlapping cytological features makes it difficult 
to separate a follicular carcinoma from an adenoma. De Matos and co-workers (101), used the 
three markers CK 19, GAL3 and HBME1 together and demonstrated in a clinical study 
population that it was possible to make the diagnosis of PTCs in 81/84 (96.5%) and of FTCs 
in 24/38 (63.1%). A review by Sanabria et al (102) concluded that “galactin-3 is not an 
absolute marker for identifying malignancies on cytologically indeterminate thyroid nodules 
(follicular pattern), although it could be used as a useful supplementary marker”. A study by 
de Micco et al (103) confirmed that immunocytochemistry with thyroid peroxidase is better 
than HBME1 for diagnosis of malignancies on FNAB from the thyroid gland. Griffith et al 
(104) have in an expert review evaluating studies presenting  IHC biomarker panels 
concluded that “the use of diagnostic biomarker panels has shown only marginal improvement 
in performance compared with the best individual biomarkers themselves”. The information 
achieved from IHC testing will, when promising markers are found, be applied to FNAB 
specimens.  There are, however, still many pitfalls when performing immunocytochemistry, 
and no “magic” markers has been found. 
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Molecular markers 
The mitogen-activated protein kinase (MAPK) pathway (figure 3) in cancer progression and 
in promotion of cancer growth is well established (105). Mutations in this pathway are found 
in > 70% of papillary carcinomas involving RET/PTC rearrangement and point mutations of 
the BRAF and RAS genes. Mutations of the BRAF gene have been found in a variety of 
human cancers. In thyroid tumors, the BRAF mutation occurs only in papillary carcinomas 
and a subset of anaplastic thyroid carcinomas. The prevalence of BRAF V600E mutation has 
ranged from 29% to 83% in different series of PTCs (106;107). BRAF mutations have not 
been detected in any FTC (108). Several studies have demonstrated a strong association 
between BRAF mutation and poor clinicopathological outcome (109;110) (111). A close 
relationship has been demonstrated between BRAF mutation and extra thyroidal extension, 
lymph node metastasis and advanced TNM stage of PTC, and these factors have been 
associated with increased rates of recurrence and mortality of thyroid cancer (112-114). 
BRAF mutation is most commonly associated with the aggressive tall-cell variant and the 
classic variant of PTC and least commonly with the less aggressive follicular variant of PTC 
(115). However, Cheng and co-workers (116) found that within each morphologic subtype, 
BRAF mutation alone did not predict aggressive behaviour. Their data emphasized the 
importance of detailed histotyping in parallel to proteomic and mutational characterization in 
defining cancer behaviour.  The evaluation of BRAF mutation status preoperatively may 
assist in the decision-making in diagnosis, on initial surgical management, on initial 
radioiodine treatment and in follow-up of patients with PTC. 
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Figure 3: 
Key components of the MAPK/ERK pathway. Epidermal growth factor binds to EGF receptor in the cell 
membrane, starting the cascade of signals. Signals enter the cell nucleus and causes transcription of DNA which 
is then expressed as protein. The mutation of the BRAF gene results in constitutively activation of the pathway 
causing tumorigenesis. 
 
Unlike PTC, RET and BRAF do not play any role in the pathogenesis of FTCs. FTCs show a 
predominance of RAS mutations, PAX8-PPAR rearrangements and aneuploidy. PAX8-
PPAR rearrangement is found in 30-40% of FTCs of conventional type (117). Additionally 
PAX8-PPAR rearrangement has been detected in a high percentage of cases (37.5%) in 
follicular variant of PTC (FVPTC) (118;119) whilst the prevalence in oncocytic carcinomas is 
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lower (120;121). PAX8-PPAR rearrangement induces a strong over expression of PPAR 
protein (122). However, the cellular impact of PAX8-PPAR rearrangement in thyroid is not 
yet fully characterized. A recent meta-analysis of all FTC outcomes data reported in the 
literature, indicated that 68% of FTC-expressing PAX8-PPAR fusion protein were minimally 
invasive, suggesting that most PAX8-PPAR fusion protein-expressing tumors were more 
likely to be minimally invasive than tumors that fail to express this fusion protein (123). The 
PPAR protein can be detected by immunohistochemistry (122;124).  
 
Point mutations of the three RAS genes, H-RAS, K-RAS and N-RAS are not restricted to a 
particular type of thyroid tumor and are found in FTCs (40-50%), PTCs (10-20%), and FTAs 
(20-40%) (33). PTCs harbouring RAS mutation almost always have the follicular variant 
histology (125;126). The three genes encode highly related 21-kDa proteins located at the 
inner surface of the cell membrane participating in the transduction of signals arising from 
tyrosine kinase and G protein-coupled receptors. When bound to guanosine triphosphate 
(GTP), MAPK and other signalling pathways, such as PI3K/AKT, are activated. As a result of 
the point mutations in the specific domains of the RAS genes, the mutant protein becomes 
permanently switched in the active position, thus chronically stimulation downstream targets 
(121). RAS mutations are not suitable as diagnostic marker for FTC due to occurrence with 
significant prevalence in FTA and the follicular variant of PTC. 
 
Treatment of differentiated thyroid carcinoma and metastases 
Surgery 
The standard surgical treatment of well-differentiated carcinoma is total (or near-total) 
thyroidectomi (90). For patients with well differentiated solitary carcinomas less than 1cm in 
diameter with no evidence of nodal or distant metastases, and no history of previous radiation 
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exposure, lobectomi is considered sufficient (90). Metastases to loco-regional lymph nodes 
has been found in 20-90% of patients with PTC (97). Consequently prophylactic bilateral 
central neck dissection to remove potential lymph node metastases has been recommended on 
patients with a preoperative diagnosis of PTC (127;128). Patients with lymph node metastases 
in the lateral neck compartment should be treated with en-bloc resection of the involved 
compartment rather than selective dissection (“berry-picking”) to reduce the risk of local 
recurrence (129). In patients who have undergone lobectomy or subtotal thyroidectomy, a 
completion thyroidectomy is advised in the cases with a potential for recurrence. These cases 
include PTCs with a diameter larger than 1 cm, multifocal tumours and FTCs demonstrating 
more than minimal capsular invasion (130).  
 
Therapeutic dissection of positive lymph nodes identified on physical examination and 
confirmed by ultrasonography or FNA cytology/Tg-FNAB of a patient with PTC, decrease 
the incidence of loco regional recurrence, prevent serious sequelae and possibly improve 
survival (131;132). The role of elective prophylactic central compartment lymph node 
dissection for overt nodal metastases remains a matter of debate (132;133). Some studies have 
shown that performing a central lymph node dissection in addition to total thyroidectomy has 
resulted in an increased rate of transient hypoparathyroidism (134-136). Revision surgery of 
the central compartment increase the risk of permanent injury to the parathyroid glands, and 
have been reported ranging from 0% to 9% (137) (138;139). 
 
Percutaneous ethanol injection (PEI) treatment 
PEI treatment has been introduced as an alternative to surgical resection of lymph node 
metastases from PTC (140). However, the numbers of PEI treated lymph nodes are small and 
the results have to be confirmed in larger series. 
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Radioiodine (RAI) Ablation 
Thyroid epithelial cells are capable of intracellular concentrating iodide as a substrate for 
thyroid hormone synthesis, which is a prerequisite for the unique radioiodine treatment.  
In Western countries radioactive iodine in the form of 131I has since 1946 been administrated 
postsurgical to destroy possible thyroid residue in the thyroid bed (thyroid ablation). There are 
several reasons for such thyroid remnant ablation. RAI may destroy residual microscopic 
metastases and normal thyroid tissue destined to become malignant (141). A few years ago, 
RAI ablation was recommended routinely after total thyroidectomy in order to get better 
control with the Tg measurements.  Additionally, a large remnant may obscure 131I uptake in 
cervical or lung metastases. However, RAI ablation is clearly associated with acute and long-
term side-effects. In a recent time trend analysis of RAI used in a cohort of 189 219 patients 
with DTC treated in US between 1990 and 2008, a significant increase in the proportion of 
patients with DTC receiving RAI-treatment was found (142). According to this study, more 
than a third of patients with low-risk tumors received RAI. The most common chronic side 
effect after RAI treatment is reduced saliva production (143). A major risk of RAI therapy is 
bone marrow suppression (144). The risk of secondary primary malignancy has been shown to 
be increased after RAI exposure, and a strong relationship has been found between cumulative 
dose of RAI and risk of cancers of bone and soft tissue (145;146). There is also an increased 
risk of developing leukaemia (141;146). The benefits of using RAI in low-risk patients are 
debated (147;148), and according to the newly established guideline by Japanese Society of 
Thyroid Surgeons and Japanese Association of Endocrine Surgeons, RAI is not recommended 
to low-risk patients due to excellent prognosis (149). This is in line with the revised American 
Thyroid Association Management Guidelines (91) not recommending RAI ablation for 
patients with unifocal cancer < 1cm without other higher risk features. 
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Thyroid Hormone Suppression of TSH 
According to European consensus for the management of patients with DTC (90) is TSH-
suppressive therapy mandatory in patients with evidence of persistent disease (including 
detectable serum Tg and no other evidence of disease). The risk of recurrence in low-risk 
patients subsequent to a cure has been reported to be low (<1%). The aim for serum TSH level 
is within the lower part of the normal range (between 0.5 and 1.0 mU/l) (150). 
 
External Radiation Therapy 
External radiotherapy is administered to patients with undifferentiated (anaplastic) thyroid 
carcinoma. Some studies have demonstrated that external radiation therapy may improve loco 
regional control in patients with nonanaplastic thyroid cancer who have high risk features 
(151;152).    
 
Potential approaches for new therapies of thyroid cancer 
Thyroid-specific gene expression, including the ability to take up and organify radioiodine 
and to make thyroglobulin is lost during the dedifferentiation process. However, new 
therapeutic approaches to thyroid cancer are developed due to advances in molecular and 
cellular biology. Among therapeutic approaches established in vitro for restoration of 
differentiated thyroid function are redifferentiating agents and gene therapy. A multikinase 
inhibitor SU12248 (Sunitinib) has been shown to effectively inhibit signalling from RET/PTC 
kinase in experimental models and has been progressed to phase II clinical trial in 
radioiodine-refractory, unresectable DTC and MTC (153). BAY 43-9006 is another 
multikinase inhibitor which inhibits the BRAF signalling and growth of all thyroid cell lines 
carrying the mutant BRAF (154). A longer than 16-week phase II trial of BAY 43-9006 
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(sorafenib) in 30 patients with metastatic iodine-refractory thyroid carcinoma showed an 
overall clinical benefit of 77%, 70% with thyroglobulin reduction, and a median 79-week 
progression-free survival (155). Another phase II trial of sorafenib in patients with metastatic 
thyroid cancer also showed a similar antitumor activity, with a median progression-free 
survival of 15 months(156). There is, however, to date no evidence to show the antitumor 
effects of sorafenib are through the inhibition of BRAF. Sorafenib may target other kinase 
pathways such as VEGFR to inhibit tumorigenesis. Unfortunately, sorafenib has a range of 
side effects that must be taken into consideration prior to the initiation of therapy. The most 
common adverse events reported include diarrhea, hypertension, fatigue and hand-foot 
syndrome (155;156). Vandetanib, a small molecule tyrosine kinase inhibitor, targets VEGF 
receptors, RET, and at higher concentrations, the EGF receptor (157;158). Vandetanib has 
previously shown antitumor activity in a phase II study of patients with advanced hereditary 
MTC (159). 
 
Prognosis 
PTC represents about 80% of all thyroid cancers. It typically follows an indolent course with a 
10 years cause-specific survival rate of young patients (<45 years) over 98% and 90% 
regardless of age (20). For minimally invasive FTC, long term mortality is in the range 3 to 
5%. Matched for sex and age the survival curves approach those of a normal population (20). 
A number of clinicopathologic prognostic factors such as older age, larger tumor size, extra 
thyroidal invasion, lymph node and distant metastases, and aggressive tumor histologic 
subtypes such as tall cell, columnar, diffuse sclerosing variants and insular variant are 
associated with worse disease-free overall survival (78). 
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Molecular testing is well-suited as an adjunct to morphological examination because it 
requires a relatively small amount of tissue. The use of molecular markers, in conjunction 
with conventional clinicopathological risk factors might assist the prognostication of thyroid 
carcinoma and improve the efficiency of contemporary management of thyroid cancer.  
The possibility of predicting the biological behaviour of PTC is growing. Testing a FNAB 
specimen demonstrating PTC for a molecular marker profile that could accurately stratify risk 
and prognosis would be ideal. BRAF V600E mutation in PTC predicts a poorer prognosis 
(160) and a test for BRAF preoperatively can help tailoring initial and reoperative surgery. A 
recent study has showed that molecular testing for a panel of mutations may be particularly 
useful in nodules with indeterminate cytology, especially in the lowest risk subgroup of 
indeterminate cytology (161). 
 
Diagnostic follow-up after initial treatment 
Neck US-examination and serum thyroglobulin measurements are the primary and standard 
follow-up procedures for differentiated thyroid cancer (90;91). This procedure may detect 
lymph nodes as small as 2mm, but the procedure is operator-dependent. US-guided FNAB 
with immediate on-site cytological evaluation might confirm the suspicion of metastasis. In 
cases where the cytological specimen is inconclusive, Tg measurement of the wash-out 
specimen will be able to confirm metastasis in cases where morphology is not conclusive for 
malignancy (99;162;163).  
The measurement of serum Tg is crucial in the diagnostic follow-up. The method is specific 
and extremely useful. The presence of serum anti-Tg antibodies (Tg-Ab) must be determined 
concomitantly, as circulating anti-Tg antibodies may interfere and cause a false negative 
serum Tg determination (164;165). 
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Aims of the thesis 
General aim  
The main objective of this study was to analyze the diagnostic accuracy of FNAB in thyroid 
nodules. Furthermore to establish new reliable procedures for follow-up of patients with well 
differentiated thyroid carcinoma. 
 
Specific aims 
1. To evaluate the cytopathologists contribution in a multidisciplinary thyroid team. 
2. To examine if Tg measurements in needle wash-out specimens from suspicious neck 
lymph nodes increase the detection rate of metastases from PTC.  
3. To validate the effect of PEI on neck lymph node metastases from PTC including 
evaluation of the combined use of cytology and Tg measurements in needle wash-out 
specimens.  
4. To examine the accuracy of four selected immunomarkers, DDIT3, STT3A, ARG2 
and FAM129A to differentiate between FTC and FTA. 
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Material and methods 
 
Table 2. Study material       
                
Period No. patients No. Cases Cytology Histology Material Method Paper 
      samples samples       
                
1998-2003 1770 1770 1770 0 Smears Morphology I 
        443/1770  Paraffin sec. Morphology I 
        
2004-2006 145 256 256 0 Smears Morphology II 
          Wash-out TR-IFMA II 
        
 
22/145  Paraffin sec.  Morphology   II  
        
2004-2009 63 109 109 0 Smears  Morphology III 
          Wash-out TR-IFMA III 
            PEI III 
                
2004-2009 41 41 0 41 Paraffin in- Morphology IV 
          house  IHC IV 
2004-2009 29 29 0 29 Paraffin TMA IHC IV 
  7   7  0    
Fresh frozen 
tissue   WB  IV 
                
TR-IFMA= time resolved immunofluorometric assay      
PEI= percutaneous ethanol injection       
WB= western blotting        
                
 
 
Paper I 
Specimens 
The reports of 1770 FNAB specimens diagnosed at the Norwegian Radium Hospital (NRH) 
between 1998 and 2003 were obtained for the comparative analysis of experience at three 
hospitals. Four hundred and forty-three of the 1770 cases were excised for histological 
examination (Table 2). Of the 1770 specimens, 254 were obtained at the Norwegian Radium 
Hospital and 1516 were submitted from other hospitals including 424 from two local hospitals 
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evaluated in the present study (320 specimens from Hospital A and 104 specimens from 
Hospital B).  
 
Morphology 
Criteria for reporting cytology and histology diagnoses were benign, suspicious, malignant, or 
unsatisfactory. 
 
Technical Considerations 
At all three hospitals two steps of the FNAB procedure were the same: 1) clinical examination 
and localization of the target lesion and 2) ultrasound-guided sampling using a 25-gauge or 
27-gauge needle without suction. At NRH an experienced cytopathologist participated in the 
FNA procedure and performed the third step: preparation of air-dried, fixed, and Giemsa-
stained smears for immediate on-site microscopy, and the possible need for additional 
techniques. At community Hospitals A and B radiologists/technical staff performed all three 
steps, with the exception of evaluation of adequacy. At hospital A a cytopathologist was 
evaluating slides from some of the cases on-site, but the pathologist did not participate 
actively during performance of the puncture as was the case at NRH. Reports were obtained 
from the electronic pathology database (Doculive). Four hundred and forty-three of the 1770 
lesions were subsequently excised and the histological data from these cases were found 
registered in the same database. All histological specimens were fixed in formalin and 
embedded in paraffin blocks from which HE-stained sections were made. 
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Paper II 
Specimens 
A total of 256 Tg-FNAB samples from 145 patients were investigated for the assessment of 
the diagnostic utility of thyroglobulin (Tg) in fine needle aspirates (Tg-FNAB) of non-
thyroidal neck masses. All patients had one or more suspicious or indeterminate cervical 
lymph nodes in neck ultrasound. The Tg-FNAB values were compared to corresponding S-
Tg, S-TgAb, morphology of cytological smear and to histology of 46 surgical specimens. 
 
Morphology 
Cytological smears from lymph nodes were classified as inadequate or not diagnostic, cells 
suspicious for DTC metastases, cystic material with macrophages and/or irregular epithelial 
cells suspicious of metastasis from papillary carcinoma or finally as malignant (metastasis 
from papillary thyroid carcinoma or other malignancies). Histologic diagnosis was performed 
according to WHO classification (20). 
  
Technical Considerations 
All FNAB specimens were obtained with a 27- or a 25-gauge needle under ultrasound 
guidance and a free hand puncture technique without suction. Cytological smears were made, 
air-dried and stained with DiffQuick. The sample needle was immediately rinsed with 500 μl 
matrix buffer or 0,9% saline. Washouts were subsequently subjected to thyroglobulin 
measurement. Time resolved immunofluorometric assay (TR-IFMA) for Tg was performed in 
the Department of Medical Biochemistry, Rikshospitalet-Radiumhospitalet (today included in 
Oslo University Hospital), and was based on two monoclonal antibodies and performed in 
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streptavidin-coated 96 well microtiter plates. Monoclonal antibodies were raised essentially as 
described for neuron specific-enolase (NSE) (166) using purified Tg from a human thyroid 
gland as antigen. Tg antibodies were determined by Anti-TGn or Anti-TGn Kryptor from 
BRAHMS (Berlin, Germany).  
 
Immunoassay 
Immunoassay is an analysis used to protein detection utilizing the interaction between a 
known antibody and the antigen (analyte) of interest. The antibody has to be labelled in a way 
that is easily detectable. The antigen should be detected both when it is present in low 
concentrations and also when it is present in excess. The background may be a challenge, 
especially when the antigen is present in low copy numbers. This is the case in biological 
samples containing a huge number of different proteins. Time-resolved immunofluorometric 
assay offers an ideal way of removing unwanted background fluorescence with a consequent 
increase in sensitivity. A fast light pulse is used to exite a fluorescence probe whose exited 
state has a decay time of between 100ns and 1 μs. The non-specific background fluorescence 
with a decay time of less than 10ns is discriminated against by using a gated detection system 
witch measures the fluorescence after the background decay is reduced almost to zero. 
Luminescent lanthanide complexes have exceedingly long-lived luminescence delivering 
greater assay sensitivity and a broader dynamic range. The immunoreaction may occur on a 
solid phase (heterogeneous) or in solution (homogeneous) and the antibody-antigen binding 
may be monitored via displacement of a labeled antigen (competitive) or directly (non-
competitive). Sample matrix is an important source of background measurements in biological 
assays (serum, tissue sample), and this is particularly the case for homogeneous assays (167). 
Removal of interfering substances may rise the sensitivity in luminescence measurements.   
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The measurement of Tg-FNAB has to be ultrasensitive to be able to detect the presence of 
even small amounts of Tg. The wash-out specimens from neck lymph node FNABs is often 
minimal, and the possibility of detecting even tiny amounts of Tg is crucial when exploring 
neck lymph nodes in patients operated for PTC. The Tg-FNAB measurements must always be 
compared with serum Tg, in order to avoid false positive result due to blood contamination. 
 
A sensitive in-house time-resolved immunofluorometric assay was performed when 
measuring Tg-FNAB in study 2 and 3 (described in Paper II). We used a microtitre plate-
based, dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) in a 
heterogeneous non-competitive format. In this system the detection antibodies are carrying the 
lanthanide, and the fluorescence are measured after a reaction including an enhancement 
solution.  The chelated lanthanide Eu3+ was chosen to produce luminescence. To obtain 
minimal interference from human anti-Tg antibodies in serum when used in the assay for Tg, 
hybridomas were selected in presence of autoantibodies. Additionally, the immunoreaction 
was carried out on a solid phase (microtitre plate) to further reduce the interference. 
Combined with the morphological evaluation of FNAB smears this approach to the 
measurements increased the assay sensitivity of the Tg-FNAB examinations and delivered a 
broader dynamic range. 
 
Paper III 
Specimens 
Samples from 124 metastatic neck lymph nodes from 69 patients who previously had 
undergone thyroidectomy for PTC were confirmed by US-guided cytological biopsy and or by 
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raised levels of thyroglobulin (Tg) in wash-outs from cytological specimens from June 2004 
through December 2009. Three patients were excluded due to lack of follow-up and three 
patients (eight metastases) were reassigned for surgery, leaving 63 patients with 109 lymph 
nodes in total for the treatment with PEI as monotherapy. 
 
Morphology 
The Bethesda classification system was used when reporting FNAB specimens (92).  
 
 
Technical Considerations 
Measurement of Tg-FNAB were obtained and handled as described for Paper II. Cystic 
lesions suspicious of metastasis were in most cases punctured several times, and multiple 
slides were made.  
 
PEI-treatment was performed in all the metastatic neck lymph nodes by injection of 0.1-1.0 
ml of 99.5 % ethanol guided by US. PEI was performed by one of three radiologists dedicated 
to US examination of the neck. The amount of ethanol injected was depending on the size of 
the lymph node, and in larger nodes the needle was repositioned into different parts of the 
node.  
 
Paper IV 
The specimens as well as the performance of immunohistochemical staining, antibody 
preparation, 125I-peptide displacement assays, western blotting, production and 
characterization of antibodies are all described thoroughly in the paper. 
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Specimens 
For the immunohistochemical study 30 cases from primary tumors diagnosed in the 
Department of Pathology at The Oslo University Hospital were included. All specimens were 
originally submitted for diagnostic purposes. The 30 cases consisted of 15 follicular 
carcinomas and 15 follicular adenomas. Follicular neoplasias with oncocytic differentiation 
were not included, and cells demonstrating oncocytic differentiation were not included in the 
evaluation. To investigate whether the staining of the normal thyroid tissue adjacent to the 
tumours was influenced by the staining of the tumours (“overspill”), slides from 11 cases of 
normal thyroid tissue from thyroid lobes not harbouring pathological findings were 
immunostained. Additionally one sample from a lymphoid nodule was included in this 
immunostaining. Tissue micro arrays (TMA) (US Biomax Inc, Rockville, USA) 
(www.biomax.us) were included when staining for each of the four antibodies. One set of the 
TMA-slides (serial TH802) contained samples from normal thyroid parenchyma and the other 
set (serial TH804) of slides were having samples from thyroid cases with pathological 
findings including eight FTCs and 21 FTAs.  
 
Morphology 
Histologic diagnosis of the in-house cases was performed according to WHO classification 
(20). 
 
 
Technical Considerations 
The in-house cases and the histological specimens referred to our hospital were fixed in 
neutral phosphate buffered formalin and embedded in paraffin blocks from which HE-stained 
sections were made. The tissue specimens from Biomax were preserved in neutral phosphate 
buffered formalin for 24 hours. The tissue specimens in-house were preserved in 4% buffered 
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formalin. The preservation time for the in-house cases was variable, but within the range of 2-
5 days.  
 
Antibody preparation and 125I-peptide displacement assays evaluating the affinity for the two 
homemade monoclonal and polyclonal antibodies as well as the Western blotting on tissue 
samples and cells from a follicular carcinoma line (FTC-133, EACC, Salisbury, UK) were 
performed at the Department of Medical Biochemistry at NRH at Oslo University Hospital. 
Immunohistochemical staining was performed at the Pathology Department using buffer AR-
10 (Biogenex, San Ramon, CA) in a steamer for 10 minutes to achieve antigen retrieval.  
Immunodetection was undertaken using Dako automated staining system (S3400 Dako, 
Carpinteria, CA, USA) using EnVision+ HRP reagents (K 4007 and K4011, Dako). 
The inclusion of specimens handled in two different laboratories was important to avoid 
preanalytical variability influencing the result. Both in-house cases and TMA-specimens were 
handled according to standardized preanalytical methods for formalin fixation and paraffin 
embedding. The laboratory staffs performing the IHC were highly experienced and the 
staining and immunodetection system used was automated and identical to what was used by 
the research group(168;169) presenting the results we were trying to validate (DAKO). Some 
proteins are relatively stable in paraffin-embedded tissue blocks but can be rapidly deteriorate 
once sectioned, thus duration of fixation can be of importance for the results (170). In our 
study, all slides were sectioned immediately before doing IHC, thus minimizing the 
possibility of protein deterioration. In our study endogenous peroxidase activity was 
suppressed by pretreatment with 0.03% hydrogen peroxide, and the background were “clean” 
evaluating IHC both in-house cases and TMA-specimens.  
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Statistical methods 
The data were analyzed using the Statistical Package for the Social Sciences (SPSS), version 
170 17.0.1 for Windows (SPSS Inc., Chicago, IL, USA). 
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Main Results 
Paper I. Fine-Needle Aspiration Cytology of the Thyroid Gland. Comparative Analysis 
of Experience at Three Hospitals 
The fraction of unsatisfactory FNA specimens from three hospitals with differences in skill of 
the performing physicians was compared. A substantially higher fraction was detected at 
community Hospital B where several radiologists, generally with limited experience and skill, 
were performing the FNAB, compared to NRH and community Hospital A (21.2 %, 7.9 % 
and 5.9%, respectively) employing a few dedicated radiologists. 
 
Paper II. The Usefulness of Detecting Thyroglobulin in Fine-Needle Aspirates From 
Patients With Neck Lesions Using a Sensitive Thyroglobulin Assay 
We found the combination of FNAB cytological examination and measurement of Tg in 
FNAB washout from cervical lymph nodes in patients with PTC to be highly sensitive and to 
give important information when the cytological morphology was not conclusive concerning 
the demonstration of metastatic cells. This was particularly the case for cystic metastases (Tg-
FNAB was positive in 25 specimens with suspicious or cystic cytology).  
Serum thyroglobulin antibodies appeared to have ignorable effect on the performance of Tg-
FNAB. The combined use of cytomorphology and Tg measurements in needle wash-out 
specimens was important in follow-up of the patients treated with PEI (Paper III).  
 
Paper III. Efficacy of ultrasound-guided percutaneous ethanol injection treatment in 
patients with a limited number of metastatic cervical lymph nodes from papillary 
thyroid carcinoma 
Metastatic neck lymph nodes in papillary thyroid carcinoma can be completely eradicated by 
ultrasound-guided percutaneous ethanol injections (PEI). US-guided PEI-treatment is an 
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excellent alternative to surgery in patients with limited cervical nodal metastases. The PEI 
technique applied is an outpatient procedure and in our study only one patient needed 
injection of local anaesthetic during a session. All patients were discharged immediately after. 
The efficacy of the PEI-treatment was evaluated by US of the lymph nodes treated. Excellent 
indicators were disappearance of the lymph node, size reduction and reduction or absence of 
vascularity in the lymph nodes. The efficacy was also confirmed by the combined use of 
cytomorphology and Tg measurements in needle wash-out specimens. 
 
Paper IV. ARG2, DDIT3, FAM129A and STT3A immunohistochemistry is not useful for 
the differential diagnosis of thyroid follicular tumors 
This study did not succeed in an attempt to confirm the results from earlier studies (168;169) 
concluding that four biomarkers (DDIT3, STT3A (ITM1), ARG2 and FAM129A (C1orf24) 
were able to distinguish between follicular adenoma and follicular carcinoma. No significant 
difference was found when evaluating the binding of the antibodies in benign follicular 
adenomas compared to follicular carcinomas. Additionally, binding of these four biomarkers 
was also observed in normal thyroid parenchyma adjacent to the tumors and in slides from 
separate specimens of normal thyroid parenchyma. 
The expression levels of ARG2, FAM129A, DDIT3 and STT3A in FTA and FTC biopsies 
using western blotting were, to a great extent, in agreement with our observations using 
immunohistochemistry.  
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Discussion 
In all four papers included in this thesis, the pathologist played an important role in collecting 
and evaluating the specimens.  
Paper I 
When we performed this study only one relevant report regarding the importance of adequate 
training of the person obtaining FNAB specimen was published (171). During the subsequent 
years great effort has focused on the field of standardizing and quality assuring of FNAB from 
thyroid lesions, both institutionally, nationally and internationally. National Guidelines for 
Management of Well-Differentiated Thyroid Carcinomas were published in 2006 (172). 
These guidelines are based on institutional (NRH) and national experience as well as on 
American and European guidelines (90;127).  
 
This paper highlights the importance of the skills of the participating members of the 
multimodal thyroid group. Experience and skill of the radiologist performing the ultrasound 
examination of the thyroid gland and neck is obligatory to achieve representative high quality 
FNAB specimens. The same cytopathologists participated in the diagnostics of specimens 
from thyroid lesions from all three hospitals. We were able to compare the fraction of 
satisfactory specimens from all locations. US examination and FNAB of the thyroid and neck 
was, with few exceptions, performed by one dedicated and skilled radiologist at community 
Hospital A. At NRH two or three radiologists participated in the US examinations and 
FNABs, whereas at community Hospital B several radiologists were involved. The number of 
FNABs performed during the six year of this study was three times higher at community 
Hospital A (n=320) compared to community Hospital B (n=104). According to these 
numbers, less than 20 FNABs were performed at community Hospital B annually.  
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At NRH, an experienced cytopathologist always participated in the FNAB procedure and 
immediately took care of the specimen for correct smearing, fixation and staining of slides 
followed by on-site microscopy. In cases demonstrating inadequate material, the radiologist 
was advised to repeat the procedure with the aim to achieve sufficient diagnostic material. 
Thus, the radiologist received immediate feed-back on the specimens achieved and could 
thereby improve the way of performing FNAB. Furthermore, this approach minimized 
confusions and enhanced effective communication between radiologist and cytopathologist.  
At community Hospital A, both the radiologist who performed the majority of the US 
examinations including FNABs and the technical staff, regularly had the possibility to consult 
a cytopathologist, thus getting advice concerning technical procedures for making high quality 
smears, fixation and staining. A cytopathologist appeared only once weekly at the radiology 
department, and was occupied evaluating specimens from a broad spectre of lesions. She was 
not able to participate on-site when fine needle aspiration of the thyroid lesions was 
performed. At community Hospital B, inexperienced technical staff made the smears. All 
specimens were submitted to our department at NRH for evaluation. No information 
concerning the potential need for repeat FNAB was available to the radiologist when the 
FNAB was performed. The need for repeat FNAB implied calling up the patients, including 
several patients with a long distance to travel from their home to the hospital. In this study we 
did not aim to decipher which of the mentioned factors that contributed the most to the 
substantial difference in percentage of unsatisfactory specimens at community Hospital B 
compared to NRH and community Hospital A.  
 
The national and international guidelines for management of patients with thyroid nodules and 
differentiated thyroid cancer strongly recommends that thyroid ultrasound should be 
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performed in all patients with known or suspected thyroid nodules, and that ultrasound should 
be used to guide when performing FNAB (90;91;172). In nodules with cystic changes, 
fibrosis and/or calcifications, US-guidance can clearly target the needle to the cellular/solid 
portion of the lesion to retrieve diagnostic material. In one study of prevalence and 
distribution of carcinoma in patients with solitary and multiple thyroid nodules on 
sonography, the likelihood of thyroid cancer per patient was found to be independent of the 
number of nodules, underscoring the importance of US-evaluation as a guidance for the 
FNAB (22). Some studies state that on-site presence of a cytopathologist or cytotechnologist 
to immediately assess specimen adequacy and representativeness may decrease the number of 
needle passes (94;173). Using combined US-guided FNAB and on-site evaluation, rates of 
inadequate samples are reported to be low, varying from 2.8% to 4% (174;175). On-site 
evaluation of FNAB smears may be responsible for cost savings avoiding repeated aspirates. 
Indirect socioeconomically cost savings include reduced time off work, and shorter hospital 
stays. Furthermore, when the on-site evaluation reveals a diagnosis of thyroid carcinoma, a 
more thorough US examination of the neck for lymph nodes may contribute to an efficient 
preoperative management before operative procedure.  
 
Concerning the technical aspects of the FNAB-procedure, studies have demonstrated that the 
use of needles of 25-27-gauge and non aspiration method (Zajdela-technique) (176) 
minimizes pain and reduces blood contamination (94). Some clinicians suggest, in a recent 
study, that the use of a stylet needle may limit the amount of blood flowing into the needle 
and thus improve the diagnostic yield (177;178). In a study by Redman et al (96), the 
inadequacy rate varied significantly among physicians, being lowest (3%) when pathologists 
and endocrinologists at teaching hospitals co-operated using US-guided FNAB. The 
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inadequacy rate was highest when FNAB was performed by surgeons (18%) and community 
physicians (6%) without US guidance. 
 
Paper II  
This study demonstrates the utility of using Tg-FNAB measurement in combination with 
cytology to reveal metastases from PTC to neck lymph nodes. The measurement of Tg-FNAB 
was proved to be particularly useful in cases with cystic metastases and in cases with 
indeterminate cytology.  
 
The usefulness of thyroglobulin detection in FNAB from neck lesions was described by 
Pacini and co workers almost 20 years ago (99). However, except for one paper by Frasoldati 
et al 1999 (162), the usefulness of this method in diagnostics is barely described in the 
literature before 2003. The multidisciplinary team at the Norwegian Radium Hospital 
introduced measurement of Tg-FNAB as early as March 2004. Due to the uplifting experience 
and results, the method was 2006 implemented as a routine in the diagnostic procedure of 
diagnosing neck lymph nodes at our hospital. This implementation is in line with international 
guidelines. The European Thyroid Association (90) recommends use of the FNA 
thyroglobulin assay to confirm suspected lymph node metastases. By contrast, in the 
American Thyroid Association guidelines (127), for the work-up of patients with 
differentiated PTC, measurement of thyroglobulin levels in FNA wash-out fluid is not even 
considered. The lack of consensus possibly reflects the fact that the FNA thyroglobulin assay 
has never been standardized. As described in Paper II, Tg-FNAB measurement should always 
be compared with Tg values in serum. In the years following our report several other groups 
have confirmed our results, supporting the usefulness of Tg-FNAB in diagnosis of 
differentiated thyroid carcinoma nodal metastases (179-186). 
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Tg-FNAB positive results must, for several reasons, be interpreted cautiously. Not all 
pathological lesions on the neck are lymph node metastases. And not even when these lesions 
are Tg-FNAB positive, can we make a diagnosis of malignancy. Additionally, the finding of 
epithelial cells suggestive of follicular epithelium in smears from a neck lesion outside the 
thyroid bed has to be interpreted cautiously. The demonstration of a mixture of lymphoid cells 
and follicular cells in smears from a neck lesion outside the thyroid gland, does not always 
implicate metastasis from PTC. In the central compartment of the neck there is a possibility of 
a thyreoglossal cyst and in the lateral compartments the finding could be consistent with 
aberrant benign thyroid parenchyma. The finding of a mixture of lymphoid cells and follicular 
cells with irregular nuclei in neck nodules outside the thyroid gland in patients shown to have 
extensive Hashimoto thyroiditis is, to our experience, a diagnostic pitfall. This underscores 
the importance of adequate clinical information and a close collaboration between the 
clinician, the radiologist and the cytopathologist. 
 
Of the samples in our study investigated before thyroidectomi, two samples had false positive 
Tg-FNAB; one patient with differentiated thyroid carcinoma (but no neck lymph node 
metastasis was found after histological examination) and one patient with benign thyroid 
disease. We do not know the reason for this false positive Tg-FNAB. In patients who have the 
whole or part of the thyroid gland intact, Tg leakage into the lymph may occur as a 
consequence of clinical or ultrasonographical examination, causing detectable Tg in lymph 
node FNAB wash-out specimens. Theoretically the patients could carry a DTC 
micrometastasis, and in the case of benign thyroid disease, the primary tumor might have been 
so tiny that it was found neither at gross examination nor at microscopy. In both cases the 
patient was followed. No malignant tumor has so far been verified. 
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The interference of TgAb when measuring serum Tg may be a technical problem, comprising 
the use of serum Tg as a tumor marker test for DTC patients with TgAb (163). Boi et al 
assayed TgAb together with Tg in FNAB wash-out specimen in eight patients with positive 
serum TgAb, and showed that TgAb were detected in FNAB washout fluid in two of these 
patients. Tg-FNAB concentration were found to be lower in these two specimens than in those 
found in TgAb negative FNAB wash-out specimens. The concentration of Tg-FNAB 
remained, however, clearly above cutoff levels even in the presence of detecable TgAb in 
FNAB washout specimens. We did not find TgAb in the wash-out specimens, and 
consequently, we interference with TgAb was not a problem in our samples. 
 
When demonstrating Tg in wash-out from lymph nodes in the central neck department in the 
case of diagnosed PTC, surgery will automatically include resection of central neck lymph 
nodes. However, a comprehensive bilateral resection of the central neck compartment lymph 
nodes may have been performed in any case. In contrast, resection of lymph nodes in the 
lateral neck compartment is seldom performed prophylactic. When metastasis to lymph nodes 
in the lateral neck compartment is revealed, by FNAB or Tg-FNAB, or findings are 
suggestive for metastasis in the lateral compartment, the surgery will become much more 
extensive, implying a risk for higher morbidity. When no primary carcinoma is revealed in the 
thyroid gland, a positive Tg-FNAB must be interpreted cautiously. The manipulation of the 
thyroid gland when examining the neck may, as earlier mentioned, cause a detectable 
 Tg-FNAB. Furthermore, when performing the FNAB on lymph nodes located in the central 
neck compartments, the needle may be contaminated with Tg while passing through normal 
thyroid parenchyma. When S-Tg is high, contamination with blood in the FNAB may give a 
detectable Tg-FNAB.  To avoid unnecessary thyroidectomies in cases displaying detecable 
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Tg-FNAB caused by contamination, all candidate cases for surgery should be discussed in a 
multidisciplinary meeting. The absence of radiological findings suspicious of thyroid cancer 
combined with a negative cytology from the lymph node examined may prevent surgical 
intervention in anticipation of a more extensive investigation. 
 
Paper III  
This study has shown that US-guided PEI treatment of metastatic lymph nodes may be an 
excellent alternative to surgery in patients with a limited number of neck metastases from 
PTC. 
 
Percutaneous ethanol injection has been in use for treating certain types of tumors 
(parathyroid adenomas, metastatic liver lesions, small hepatocellular carcinomas and other 
benign endocrine neoplasms) for almost 30 years (187-189) (190-192). Furthermore, PEI has 
been shown to represent an effective alternative to surgery and RAI treatment of autonomous 
functioning thyroid nodules (193-195)and has also been proposed for the treatment of cold 
benign thyroid nodules (196;197) and thyroid cysts (198-200). 
 
In 2002, Lewis and co workers (140) presented a study which concluded that sonographically 
guided percutaneous ethanol injection is a valuable treatment option for patients with limited 
cervical nodal metastases from PTC. We established the PEI procedure as treatment for 
cervical nodal metastases at NRH in June 2004. The treatment has since then been in use in 
the everyday practice at an out-patient clinic at the NRH. As far as we are informed, no other 
hospitals in Norway or even in Europe are practicing PEI treatment routinely of neck lymph 
node metastases from PTC. As being one of few hospitals practicing PEI treatment of 
metastatic neck lymph nodes, our study was acknowledged in an editorial by Ian D. Hay and 
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J. William Charboneau at Mayo Clinic in the same issue of JECM publishing our manuscript 
(201). At NRH the PEI treatment has even been given to a few patients with local recurrence 
of PTC, unsuitable for surgery and lacking response to RAI-treatment. The recurrence of 
tumor in these patients has caused compressive symptoms, and the administration of ethanol 
has managed to shrink the lesions with transient relief of the symptoms. The treatment has 
been repeated several times due to recurrent growth. According to these up-lifting results, the 
criteria for the use of PEI treatment may widen, and foci of recurrent papillary carcinoma 
inaccessible to surgery can be a target for PEI treatment.  Additionally, small foci of primary 
PTC in patients refusing surgery may be treated with PEI. 
 
Preliminary, rapid, on-site cytologic diagnosis made it possibel to give PEI treatment 
immediately. This increases the safety of the procedure as well as optimizing utilization of 
procedure rooms and imaging facilities. Whereas no high-level evidence exists to define 
whether the addition of central neck lymph node dissection (CLND) to total thyroidectomy 
for PTC confers greater risk of permanent hypoparathyroidism or permanent nerve injury 
(132), reoperation in the central neck compartment for recurrent PTC has a considerable risk 
for permanent injury to the recurrent laryngeal nerve and the parathyroid glands than initial 
total thyroidectomy with or without CLND (202). The incidence of temporary 
hypoparathyroidism ranges from 0.3% to 13% in several large series (137;203;204). 
Permanent hypoparathyroidism is a devastating and disabling complication that can occur 
with reoperative thyroid surgery with a reported incidence of 0% to 3.5% (137) (138). 
 
All patients included in our study received at least one RAI-treatment after surgery. Metastatic 
lymph nodes were diagnosed after surgery and RAI-treatment. Pathological lymph nodes were 
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detected when performing US examination at follow-up and PTC metastasis was verified with 
cytomorphology and/or positive Tg-FNAB.  
 
The benefits of surgery (reoperation) and RAI-treatment of patients with differentiated thyroid 
carcinoma might be outweighed by the risk of complications, which have initiated the search 
for an alternative treatment of local neck recurrence of PTC. The interest in finding an 
alternative treatment is driven by the fact that some PTCs are unresponsive to RAI. The 
decision whether to give RAI-treatment or not can be difficult because of conflicting reports 
of RAI treatment and medical uncertainty due to the lack of long-term randomized controlled 
trials (205). Postoperative RAI-treatment can be avoided in low-risk patients and should be 
individualized. The RAI-treatment is expensive and this approach may reduce the costs.  
 
In our study PEI treatment was cost-effective, efficient, and cheap and could also be 
performed at an out-patient basis. No follow-up report after long observation period has been 
performed after PEI treatment of neck lymph node metastases from PTC, but short- and 
intermediate time follow-up has not revealed any serious side-effects. When performing PEI, 
the cost of cytological examination of neck lesion with US guidance based on Dutch Health 
Care Tariffs (2010) is €232 (206) and the additional cost for the tiny amount of ethanol given 
is diminutive.   
 
Paper IV 
Thus, no new procedures have been implemented as a result of the study of the markers 
DDIT3, STT3A, ARG2 and FAM129A. We have been reminded of the fact that no “magic 
tumor marker” able to differentiate between benign and malignant follicular tumor can be 
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included in the established immunohistochemical panel without being verified by new 
independent observations. In our study, evaluation of the histological slides was performed 
independently by two pathologists. All discordant cases were re-evaluated using a multi-
headed microscope, and consensus was always achieved. Discrepancy in the diagnosis when 
reviewing thyroid specimen is frequent, and was found to be 18% in one study by Hamady et 
al (208). Since major therapeutic and prognostic modifications may be adjusted according to a 
second histological opinion, cases of suspected thyroid cancers should be reviewed in a 
multidisciplinary meeting, and this has been done at NRH. 
 
In molecular studies large numbers of people have been screened for thousands of genes with 
the aim to identify diagnostic and prognostic markers for thyroid cancer. When considering 
potential new diagnostic markers, a well known problem is that the decision relies on 
published studies and can only incompletely identify possible biases in them. There is a bias 
in the fact that when a study presents “negative results”, it may not be submitted or accepted 
for publication. Journal editors should have an obligation to publish negative results. In many 
cases extensive effort has been performed to replicate the results in published works. When 
critical evidence provide that differences in reagents and methods are not responsible for the 
failure of other replication studies, these new studies should be published with the same 
matter of course. Other researchers provided with the data will be informed, so that if they 
want to investigate the same area, they can try alternatives or modifications rather than simply 
repeat results that were unpublished. Another aspect is described in an editorial by Pfeffer et 
al (207): “If the “negative results” are the consequence of some fundamental flaw in methods 
that are commonly used, further analysis by others may help uncover those flaws and lead to 
methodological improvement”. Improper use of immunologic tests can result in misdiagnosis, 
inappropriate therapy, and wasted health care resources.  
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The morphology has been, and will still be the gold standard. New techniques are often 
expensive and time-consuming. It will be an imperative that the new diagnostic techniques 
must provide information of prognostic or therapeutic significance beyond that provided by 
the current gold standard. Large multicenter biomarker studies are advisable for identification 
of novel biomarkers that may have clinical utility for thyroid cancer diagnosis. In these 
studies large patient cohorts are required for both the development and the validation of a test. 
Robust predictors may be identified through using multiple classification algorithms to select 
genes. For validation test IHC on TMAs may be useful enabling potentially new biomarkers 
to be tested on a large number of tumor samples. Validations tests should also be performed 
on a set of samples matched for different clinically variables. Comparison of study results can 
be strengthened through standardization of IHC technique and criteria for marker 
interpretation.  
 
Methodological Considerations (Paper II-IV) 
A sensitive in-house time-resolved fluoroimmunoassay previously established in the 
Department of Medical Biochemistry at Oslo University Hospital, described in Paper II, was 
chosen for the measurements of Tg-FNAB (Paper II and III). The specificity of immunoassay 
depends, as earlier mentioned, on the degree of a specific antibody to bind to an epitope 
(antigen). The monoclonal antibodies we used have high affinity for Tg. To reduce 
interference from autoantibodies (TgAb) the hybridomas were selected in the presence of 
autoantibodies. The Tg assay was also less vulnerable to interference of heterofilic antibodies 
due to modification of the solid phase mAb. The assay we used was standardized against a 
reference preparation. When performing the wash-out procedure rinsing the needle in the 
matrix buffer or different amounts of saline, the amount of specimen was variable, and the Tg 
values were evaluated without considering dilution. In contrast to several other studies 
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(181;183;209), we did not define a definite cut-off value for Tg-FNAB, as we consider it to be 
important to evaluate the results of the measurements of Tg-FNAB with regard to S-Tg and S-
TgAb. The manipulation of the thyroid gland when examining the neck may cause false 
positive Tg measurements. Thus the diagnostic significance of Tg-FNAB differs in patients 
with or without thyroid gland which should also be taken into consideration when evaluating 
the values of Tg-FNAB measurements. 
 
 
Immunohistochemical studies (Paper IV) of diagnostic markers should ideally follow 
guidelines for standardization to guarantee better methodological quality. According to 
Sanabria et al (102) diagnostic test studies should satisfy several conditions in order to yield 
reliable results; the study must be prospective, and the study must examine a clinically 
relevant population, the study must have a gold standard, the evaluation of the new test must 
be independent and blind, intraobserver and interobserver agreement must be assessed and in 
cases with multiple cutoff points, a stratified analysis with each cutoff point should be tried. 
The staining protocols and more consistent cutoff points of intensity or frequency of positive 
tumor cells remain to be standardized for many immunologic markers. The evaluation of 
immunohistochemical staining is subjective. Several grading systems for evaluation have 
been developed. Some are considering the staining of the nuclei, the cytoplasm and the cell 
membrane separately. Others are trying to quantify the intensity of the staining. To be able to 
compare our evaluation of molecular markers (Paper IV) with the results presented by Cerutti 
el al (168;169), we chose to perform the immunostaining using the same protocol as Cerutti et 
al (168). Through this, the risk that the differences in results could be explained by differing 
methodologies was minimized.  No standardization of the evaluation of the four 
immunomarkers investigated has been established. The reproducibility of the evaluation is 
diminishing with rising numbers of parameters subjectively assessed. Cerutti et al (168) 
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evaluated staining both in the nucleus and the cytoplasm, but they did not define a cut-off for 
the fraction of positive cells needed to categorize the case as positive.  When examining the 
immunohistochemical slides, we found cytoplasmic immunostaining to be the most 
appropriate. We did not find cases showing positive staining only in the nuclei. The 
immunohistochemical slides were scored in a semiquantitative manner as was performed by 
Cerutti et al (168). Additionally, we used a predetermined cutoff of 20% (<20% tumor cells 
staining = negative, 20% = positive) to unequivocally categorize cases in two groups when 
calculating sensitivity and specificity. The interobserver agreement was assessed and was 
satisfactory.  
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Conclusions 
General  
We demonstrated that experienced and skilled personnel increase the accuracy of FNAB 
specimens. Furthermore new reliable procedures for follow-up of patients with DTC were 
established. 
 
Specific 
1. The fraction of representative and diagnostic FNAB specimens from thyroid lesions 
was higher in hospitals where dedicated and skilled physicians participated in the 
ultrasound guided FNAB procedure (Paper I). 
2. Tg measurement of needle wash-out specimens from suspicious neck lymph nodes 
increased the detection rate of metastases from PTC. This was particularly the case for 
cystic metastases (Paper II).  
3. PEI of neck lymph node metastases from PTC was efficient, cheap and without side 
effects. The efficacy of the PEI treatment was confirmed by US examination 
(disappearance or reduced size and vascularity of the lymph nodes) and by the 
combined use of cytomorphology and Tg measurements (no detectable Tg) in needle 
wash-out specimens (Paper III). 
4. The four molecular markers DDIT3, ARG2, STT3A and FAM129A were not helpful 
in separating FTA from FTC (Paper IV). 
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Future Perspectives 
The future perspectives for management of patients with thyroid lesions will be dependent on 
some important assumptions being fulfilled: 
1) The engagement, knowledge and skill of all physicians involved 
2) The establishment and functionality of a multidisciplinary thyroid 
team 
3) Optimal collaboration between pathologist and bench scientists 
4) The electronic journal must allow all relevant clinical information 
to be registered and be available to the pathologist, and 
subsequently be included in the report to the clinician.  
 
The role of the Pathologist in future management of patients with thyroid lesions 
The role of the pathologist in thyroid diagnostics has changed over the last 10 years, and 
might change even more in the near future. This can be seen in the light of the three following 
fields: Personalized Medicine, Informatics and Multidisciplinary groups. In all these areas 
the thyroid pathologists are, or should be, heavily involved due to their highly specific 
knowledge of anatomic pathology, tumor biology and management.   
 
Personalized Medicine 
Personalized medicine is sometimes referred to as personalized health care that according to 
the Personalized Health Care Expert Panel Meeting 2007 (210) is described as follows: 
”Personalized health care draws molecular- and cellular-level disease processes, health states, 
behavioural and environmental determinants and response to interventions. It applies this to 
deliver patient-specific health care that reflects individual risks and benefits of particular 
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treatments, to determine risks of particular conditions or diseases and to facilitate the 
discovery and validation of health care products and other interventions”. 
 
The impact of personalized medicine on the management of thyroid disorders is growing. 
Like malignant tumors originating in other organs, the management of lesions in the thyroid 
gland should be individualized according to both the patient’s and the nodules characteristics. 
Some describe this as the dawn of the era of personalized thyroid medicine, and the end of the 
era of ”one fits all” medicine. The knowledge of genetic, epigenetic and molecular biomarkers 
of thyroid tumors rise among scientists, and the physicians participating in multidisciplinary 
thyroid teams will need to be informed on how to utilize this new information in the care of 
their patients. It is important not only to give the thyroid patients the best treatment, but also 
to avoid using time and money on markers and treatment that do not work. The pathologists 
may act as a bridge between biomedical researchers and clinicians. The pathologist will be 
extensively involved in three important aspects of personalized medicine; the development 
and validation of novel biochemical and molecular markers, the quality assurance of 
cytological specimens, and the establishment of genetic banking systems. It is of crucial 
importance that the pathologist examines the morphology of all specimens included in studies 
using tissue samples for investigation of molecular markers. Both paraffin embedded samples 
and fresh specimens might consist of cancer tissue as well as benign parenchyma. 
Microdissection enabling the investigator to isolate tumor tissue from the benign surrounding 
parenchyma will in many cases be necessary.   
 
 The development in management of patients with thyroid tumors made the American Thyroid 
Association (ATA) to choose Personalized Medicine as their theme for their recent spring 
(2010) symposium ”Thyroid Disorders in the Era of Personalized Medicine” (211). 
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Informatics in Practical Pathology 
Pathology informatics may be defined as the discipline and practice of using electronic 
information systems to facilitate, promote, and advance the practice of pathology, as 
exemplified in pathology’s tripartite mission of patient care, physician education, and the 
understanding of disease (15). An enormous amount of studies presenting molecular analysis 
of thyroid tumors have been published. Some of the alterations discovered and characterized 
have significant diagnostic utility, and some may serve as potential therapeutic targets. As 
mentioned earlier, the molecular marker BRAF, i.e., offer help in risk stratification and can be 
potentially used to optimize surgical and postsurgical management of patients with thyroid 
cancer. The genetic markers developed for use in diagnostics are, however, not the only 
advances in thyroid pathology. The documentation of digital images make it easy to compare 
different samples and to consult outside experts, the availability of up-dated classification and 
information on-line, the immediate access to clinical and radiological reports, are all 
improvements for management of patients with thyroid lesions. 
 
The role of multidisciplinary groups in managing thyroid lesions 
A multidisciplinary team is, according to the UK Manual for Cancer Services 2004 (212), 
defined as ”a group of people of different healthcare disciplines, which meets together at a 
given time (whether physically in one place, or by video or teleconferencing) to discuss a 
given patient and who are each able to contribute independently to the diagnostic and 
treatment decisions about the patient”.  The advantages of a multidisciplinary team looking 
after thyroid cancer are well known and have been detailed in the Manual for Improving 
Outcomes in Head and Neck Cancer by the National Institute of Clinical Excellence (213). In 
a review concerning new therapeutic approaches for metastatic thyroid carcinoma in Lancet 
Oncology 2007, E. Baudin and M. Sclumberger conclude “that to increase the accrual of 
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patients to trials, optimise the experimental design of the protocol, improve the 
characterisation of tumor tissues, and improve the tolerance of treatment, the participation of 
endocrinologists, oncologists, specialists of nuclear medicine, surgeons, pathologist, 
researchers, and statisticians needs to be strongly encouraged” (214).   
 
Molecular predictive markers for use on FNAB specimens 
The knowledge acquired during the recent years about molecular genetics of thyroid cancer 
has been shown to be especially useful in the preoperative diagnosis of thyroid cancer.  
On FNAB specimens the category “Follicular lesion of undetermined significance/atypia of 
undetermined significance” is defined as being heterogeneous and a class that cannot be 
classified as benign, suspicious for follicular neoplasm, or suspicious for malignancy 
according to the new Bethesda 2007 Thyroid Cytology Classification (92). The risk of 
malignancy in this group has been estimated at 5-10% and falls between benign (1%) and 
follicular neoplasm (20-30%) diagnoses. Although repeat FNAB may provide clarification, 
the use of ancillary testing can be helpful in separating cases into a high-risk group and a low-
risk group (215). In a recent prospective study (216), 967 FNAB samples were analyzed for a 
panel of mutations consisting of BRAF, NRAS, HRAS, KRAS point mutations and 
RET/PTC1, RET/PTC3 and PAX8/PPAR rearrangements. Eighty-seven mutations were 
revealed including 19 BRAF, 62 RAS, 1 RET/PTC, and five PAX8/PPAR.  BRAF, 
RET/PTC and PAX8/PPAR mutations were associated with malignancy in close to 100% of 
nodules. The negative predictive value of molecular testing indicated that the cancer risk in 
mutation-negative nodules with follicular neoplasm/suspicious for follicular neoplasm and 
suspicious for malignant cells was 14% and 28%, respectively. American Thyroid Association 
guidelines recommend diagnostic lobectomy for mutation-negative samples displaying 
follicular neoplasm/suspicious for follicular neoplasm on cytology (91). 
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Testing for point mutations on FNAB specimens, as of BRAF and RAS, can be achieved by a 
variety of molecular techniques, including probe-specific real-time PCR amplification, real-
time allele-specific PCR, direct sequencing, and colorimetric assay (121;217-220). The 
detection of chromosomal rearrangements, such as RET/PTC and PAX8/PPAR, on freshly 
collected or snap-frozen FNAB specimen can be reliably performed by reverse-transcriptase 
in a conventional or real-time mode. Nikiforov and co-workers (216) found that more than 
90% of the residual aspirated material (wash-out specimen) collected during routine FNAB 
procedure was sufficient for mutation detection. 
 
The number of incidentally diagnosed thyroid nodules will most probably increase. Thus, 
accurate markers that have a high sensitivity and specificity will be needed to make a 
significant impact on the management of thyroid lesions. Future clinical trials must, however, 
be conducted in a way that enables evaluation of the emerging biomarkers and the cost-
effectiveness of using these biomarkers routinely or selectively in management of thyroid 
neoplasms. 
 
The pathologists as a diagnostic specialist will in the future play an important role in adopting 
new diagnostic and prognostic modalities as well as in the use of informatics tools as they 
become available. 
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Errata 
 
1. There is a typing error in Paper I in Table III. The headings of the columns indicating 
which hospital the specimens originate from are wrong. The heading “B” should be 
replaced by “A”, and the heading “H” should be replaced by “B”.  
2. There is a typing error in Paper I in Abstract. The number of specimens diagnosed 
from the two community Hospitals A and B were 424, not 425 as mentioned in the 
abstract. Through the rest of the paper, the correct number of 424 is used. 
3. In Paper I, the calculated specificity for NRH and community Hopsitals A and B is 
incorrect and should be 100% for community Hospitals A and B and 99.6% for NRH. 
4.  There is a typing error in Paper III in paragraph “Patients and Methods” repeating the 
sentence “Hybridoma were selected in presence of autoantibodies in order to obtain 
minimal interference from human anti-Tg antibodies in serum when used in the assay 
for Tg”. 
5. Reference number 4 and 20 in Paper I have through an oversight been found to be the 
same reference. For this reference (by Ravetto et al) the correct page numbers in 
Cancer 2000;90 are 357-363 as written in reference number 4, not page numbers 325-
329 as written in reference number 20. 
6. Through an oversight the URL-link for reference number 210 in the Thesis has been 
found missing. The correct URL-link is: 
http://aspe.hhs.gov/health/reports/07/PHC/execsum.htm 
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Efficacy of Ultrasound-Guided Percutaneous Ethanol
Injection Treatment in Patients with a Limited
Number of Metastatic Cervical Lymph Nodes from
Papillary Thyroid Carcinoma
Arne Heilo, Eva Sigstad, Kristin Holgersen Fagerlid, Olav Inge Håskjold,
Krystyna Kotanska Grøholt, Aasmund Berner, Trine Bjøro, and Lars H. Jørgensen
Departments of Radiology and Nuclear Medicine (A.H., K.H.F., O.I.H.), Pathology (E.S., K.K.G., A.B.), and
Medical Biochemistry (T.B.), Division of Diagnostics and Intervention; and Department of Thoracic
Surgery, Division of Cardiovascular and Pulmonary Diseases (L.H.J.), Oslo University Hospital HF, 0424
Oslo, Norway; and Faculty of Medicine (A.B., T.B.), University of Oslo, 0316 Oslo, Norway
Context: Repeated neck explorations can be a difficult task in patients with recurrent metastatic
cervical lymph nodes from papillary thyroid carcinoma (PTC).
Objective: Theaimof this retrospective studyhasbeen toassess theefficacyofultrasound (US)-guided
percutaneous ethanol injection (PEI) as treatment of metastatic cervical lymph nodes from PTC.
Materials andMethods: Sixty-nine patients who previously had undergone thyroidectomy for PTC
were selected for inclusion. However, three patients were later excluded due to lack of follow-up.
Lymph node status was determined by US-guided fine-needle aspiration biopsy and/or by raised
levels of thyroglobulin inwashouts from the cytological needle. Guided byUS, 0.1–1.0ml of 99.5%
ethanol was injected into the metastatic lymph nodes.
Results: Three patients (eight metastatic lymph nodes in total) were reassigned to surgery due to
progression (multiple newmetastases), leaving 63 patients and 109 neck lymph nodes to be included.
Meanobservationtimewas38.4months(range,3–72).Atotalof101ofthe109(93%)metastatic lymph
nodes responded to PEI treatment, 92 (84%) completely and nine incompletely. Twodid not respond,
and four progressed. Two lymphnodes previously considered successfully treated showedevidenceof
malignancy during follow-up. No significant side effects were reported.
Conclusion: US-guided PEI treatment of metastatic lymph nodes seems to be an excellent alter-
native to surgery in patients with a limited number of neck metastases from PTC. This procedure
should replace “berry picking” surgery. (J Clin Endocrinol Metab 96: 2750–2755, 2011)
Papillary thyroid carcinoma (PTC) represents about80%of all thyroid cancers (1).Most PTC are indolent,
with a10-yr cause-specific survival rate of 93%regardless of
stage (2, 3). Total thyroidectomy is the most common treat-
ment. In patients with low-risk PTC, neck recurrence occurs
inup to20%(4, 5).Thebenefits of concomitant lymphnode
resection in the central neck compartment are questionable
and a matter of constant debate (6). The American Thyroid
Association recently (2009) revised their guidelines for neck
surgery onPTCpatients, concluding that “prophylactic cen-
tral-compartment neck dissection (ipsilateral or bilateral) is
recommended” (7).
Depending on size and multiplicity of primary thyroid
tumor, occurrence ofmetastatic lymph nodes in the neck, or
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distant metastases, the primary operation is followed by ab-
lation therapy with 131I. Unfortunately, radioiodine treat-
ment is often ineffective in eradicating lymph node metasta-
ses (8). Due to the mild clinical course, many patients
undergo repeated neck explorationswhen additionalmetas-
tases are revealed. Such explorations are usually challenging
due to scar formation subsequent to previous surgery, yield-
ing a higher risk of complications (9).
Ultrasound (US) and serum thyroglobulin (S-Tg) mea-
surements are the most important examinations during
follow-up after primary treatment for PTC.USmay detect
metastatic lymph nodes as small as 2 mm. Fine-needle
aspiration biopsies (FNAB) and thyroglobulin (Tg)
measurements in needlewashouts (FNAB-Tg) have high
sensitivity and specificity in verifying lymph node me-
tastases (10).
Different authors have reported good results using
percutaneous ethanol injection (PEI) in the treatment of
patients with benign thyroid cysts (11, 12) as well as
hyperfunctioning thyroid adenomas (13) and benign
parathyroid adenomas (14). In 2002, Lewis et al. (15)
reported promising results usingUS-guidedPEI treatment of
14 patients with cervical lymph node metastases. This in-
spired our multidisciplinary thyroid team at the Norwegian
Radium Hospital (NRH), and we consequently introduced
the PEImethod in 2004. Since then, three other studies com-
prising six, 16, and 27 patients, respectively, have reported
promising results (16–18).
Patients and Methods
Patients
From June 2004 through December 2009, 69 patients (27
men and 42 women) with PTC and cervical metastatic lymph
nodes were retrospectively included in this study. All patients
had undergone total or subtotal thyroidectomy in one or two
steps, followed by radioiodine ablation. Three of the 69 patients
were excluded due to lack of follow-up. Due to progression (ap-
pearance of new metastatic neck lymph nodes), three patients
(eight metastatic lymph nodes in total) were reassigned for sur-
gery. The remaining 63 patients (109 neck lymph nodes in total)
were treated with PEI as monotherapy. The median age at pri-
mary surgery was 43 yr (range, 20–76), and median age at PEI
was 52 yr (range, 21–85).
Clinical information and tumor node metastasis (TNM) cat-
egory at the time of primary diagnosis were retrospectively reg-
istered as shown in Table 1. All 63 patients had localized disease
andhadnodistantmetastasis (M0category). Fifty-sevenpatients
had undergone central neck lymph node dissection. Many pa-
tients hadalsoundergone lateral necknodedissection.However,
some had received surgical treatment in other hospitals, and de-
tailed information about surgery, including extension of the cen-
tral lymphnode dissection at primary surgery,was not available.
Subsequent to surgery, the 63 patients were grouped as N1
(carcinoma has spread to nearby lymph nodes) (n 46), N0 (no
spread to nearly lymphnodes) (n 11), andNX (regional lymph
nodes cannot be assessed) (n  6) disease. All 63 patients had
been treated with 131I once, twice, or several times (median, two
times; range, 1–10 times) with median accumulated dose of 131I
of 284 mCi (10.5 GBq) and range of 100-1406 mCi (3.7–52
GBq). Several patients (exact number impossible to determine
due to lack of clinical information from local hospital) had un-
dergone repeated neck dissections at NRH or a local hospital
after initial treatment.Onepatientunderwent seven surgical pro-
cedures in the course of 4 yr.
The interval from initial surgery toPEI treatment ranged from
6 to 384 months (median, 24 months).
None of the 63 patients included had more than three met-
astatic lymph nodes. The criteria for PEI treatment were fulfilled
for all nodes treated.
Methods
The inclusion criteria for PEI treatment of PTC patients were
as follows: 1) carcinoma cells identified in FNAB specimens
and/or elevated level of FNAB-Tg; 2) no radiological findings
suspicious of malignancy inferior to the neck; 3) record of pre-
vious treatment with 131I; and 4) detection of up to three met-
astatic lymph nodes in previously dissected neck compartments.
By US, all lymph nodes were visualized using a 12–5 MHz
broadband linear US transducer (HDI 5000 with Sono-CT and
X-res; Philips-AdvancedTechnologyLaboratories, Bothell,WA;
or Logiq 9; GE Medical Systems, Milwaukee, WI).
The FNAB procedure, guided by US examination, was under-
taken whenever a lymph node suspicious of metastatic disease was
observed.TheFNABmaterialwasobtainedusinga25-or27-gauge
needle. The smears were immediately assessed on site by an expe-
rienced cytopathologist before PEI treatment. Metastasis was con-
firmed in cytological smears and/or by demonstration of raised lev-
elsofFNAB-Tginneedlewashouts(10).TheBethesdaclassification
system was used when reporting FNAB specimens (19). In cases
with inconclusive or questionable FNAB, FNAB-Tgmeasurements
ensured that no additional lymph node puncture was necessary.
This multimodal approach including on-site US-guided FNAB ex-
aminationandcombinedTgmeasurementsofneedlewashoutswas
a prerequisite for effective subsequent PEI treatment that was per-
formed onmost patients. All lymph nodeswere grouped according
to the American Joint Committee on Cancer, having levels from
I-VII (20).
Due to promising results during the early phase of the study,
patients with metastatic lymph nodes in nondissected compart-
TABLE 1. Sixty-three patients with PTC categorized
according to TNM classification
TNM classification
when first diagnosed Total N0 N1 NX
T1 15 5 10 0
T2 16 1 13 2
T3 7 1 5 1
T4 13 2 9 2
Tx 12 2 9 1
Total 63 11 46 6
Information to classify the tumor was not available for 12 patients, and
in six patients no information was available about the lymph nodes. All
63 patients had localized disease and had no distant metastases (M0
category).
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ments were eventually included. Up to five lymph nodes were
injected if additional metastatic lymph nodes were detected dur-
ing follow-up.
US examination was performed by three experienced radiolo-
gists (A.H., K.H.F., and O.I.H.). The US images allowed antero-
posterior, transverse, and longitudinal measurements in most
lymphnodes.VascularityasdisplayedbycolorDopplerwasalways
performed before treatment and whenever Doppler control was
needed. The PEI procedure was always performed by the same ra-
diologists.Allpatientswere treatedonanoutpatientbasisandwith-
out premedication. Only one patient needed local anesthetic. All
patients were discharged immediately after treatment.
No coagulation tests were performed before the PEI treat-
ment. S-Tg, S-Tg antibodies (S-TgAb), serum TSH, and serum
free T4 were measured. S-Tg and FNAB-Tg were measured as
previously described by a time-resolved immunofluorometric as-
say (10). A low, nonspecific bindingwas obtained, and the assay
is characterized by an analytical detection limit of 0.1 g/liter
and functional sensitivity of 0.2 g/liter. Tg antibodies were de-
termined by Anti-TGn Kryptor from BRAHMS (Berlin, Ger-
many) standardized with World Health Organization First In-
ternational Reference Preparation 65/93. Tg antibodies value
above 50 kU/liter was considered positive, and 35–50 kU/liter
was considered borderline positive. The detection limit was less
than 10 kU/liter.
The PEI technique used was essentially that described by
Lewis et al. (15) using a 25-gauge needle of 4 cm attached to a
1-ml syringe filledwith 99.5% ethanol. TheUS-guided puncture
was performed by a freehand technique with the needle oriented
at an angle parallel to the transducer scan plane. In total, 0.1 to
1ml ethanolwas injected, startingwith small amounts deposited
in the peripheral part of the node and repeated several times
during needle withdrawal. In larger nodes, the needle was
repositioned into different parts of the node, and several in-
jections were performed with the intention of achieving total
ablation. All PEI-injected lymph nodes were monitored with
color Doppler to display loss of vascularization, and if nec-
essary further injections were performed in vascularized ar-
eas. The volume of injected ethanol and possible unwanted
side effects were recorded.
Treatment was considered effective when reduction in vol-
ume and/or reduction of lymph node vascularization were dem-
onstrated by US. Criteria for satisfactory PEI treatment were: 1)
complete lymph node disappearance; 2) reduction of the antero-
posterior lymph node diameter to 4 mm or less without visible
vascularization; 3) normalization of lymph node size and ap-
pearance, and in somenodes scar formation; and4)nodetectable
malignant cells in the FNAB specimens and no detectable Tg in
needle washouts.
The majority of the patients were reexamined every third or
fourth month with US. Whenever additional lymph nodes sus-
picious ofmalignancywere detected, FNABwas performed, and
the FNAB-Tg level was assessed. The malignant lymph nodes
underwent PEI treatment until satisfactory results were
achieved. If not, surgical extirpation was performed.
The study has been approved by the quality assurance com-
mittee of Oslo University Hospital.
Results
Threepatients (eightmetastatic neck lymphnodes in total)
were reassigned for surgery due to progression (appear-
ance of new metastatic lymph nodes). One of these three
patients was reassigned for surgery due to appearance of
metastatic lymph nodes in several additional levels. The
next patient received surgery after being treated with PEI
twice (after 8months), and the last patient after four treat-
ments (12 months).
In the remaining 63 patients, all 109 lymph nodes
treated with PEI were diagnosed either on cytological
smears or by FNAB-Tg measurements. Malignant lymph
nodes were localized to levels VI and VII, containing 46
and three lymph nodes, respectively. Another 37 lymph
nodes were detected in level IV, 11 in level III, four in level
Va, two in level Vb, three in level IIa, one in level IIb, and
finally two had a parapharyngeal location. The initial cy-
tology was positive in 91 lymph nodes. FNAB-Tg con-
firmed malignancy in the other 18, although smears from
12 of the 18 cases were suspicious of malignancy. Cytol-
ogy was benign in two cases, and four did not yield diag-
nostic material. Four cases without elevated FNAB-Tg
(0.1 g/liter) demonstrated malignant cells in the cyto-
logical smears. This was probably due to insufficient
amounts of material in the needle washout specimens.
The lymph node volume before treatment was in the
range of 0.01–3.56 ml (mean, 0.34). The injected volume
of ethanol in each session varied from 0.1 to 1 ml (mean,
0.4). Seventy-six metastases had pathological vascularity,
11 had normal vascularity, and 22 showed no vascularity.
In addition, 29 had microcalcifications, and 21 were par-
tially cystic at US examination before PEI treatment.
Size reduction of a PEI-treated lymph node was an ex-
cellent indicator of evaluating response to treatment. In
general, hypervascular metastases turned almost avascu-
lar immediately after terminating the ethanol injection.
Reduction or absence of vascularity was also observed in
PEI-treated lymph nodes during follow-up. Independent
of size, treatment was continued as long as vascularity
could be demonstrated. However, a few lymph nodes did
not shrink, and some even increased in size after the first
PEI treatment.
Ninety-two of the 109 PEI-treated lymph nodes with
follow-up were successfully treated. Seventy-two nodes
disappeared, and20were successfully treatedaccording to
criteria 2–4mentioned as satisfactory following PEI treat-
ment (Fig. 1). As shown in Table 2, up to five ethanol
injections were needed to eradicate the metastatic tumor
tissue. Variation in metastatic neck lymph node size rel-
ative to number of injections is also presented (Table 2).
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We evacuated fluid from one cystic metastasis before PEI
treatment.
At termination of the study, 17 neck lymph nodes still
under treatment were followed by US. Nine of these dem-
onstrated incomplete response after one or two injections
(regression). Two were nonresponders (unchanged) after
one injection, four progressed after two to six injections,
and two had recurred (Fig. 1). Table 3 shows the mini-
mum, maximum, and median diameter of all 109 lymph
nodes before treatment and the posttreatment diameter of
the 20 successfully treated lymph nodes that were still
visible.
The US findings determined whether PEI treatment
should be performed or not. Combined FNAB and
FNAB-Tg examinations on 54 neck lymph nodes that had
not disappeared were performed by US during follow-up.
In 24 lymph nodes, FNAB examination detected malig-
nant cells and/or detectable Tg in FNAB washouts that
confirmed malignancy. Thus, further PEI was needed.
Eighteen samples were negative by both methods, and the
lymphnodeswere classifiedas successfully treated.Wedid
not achieve diagnostic FNAB from two lymph nodes;
however, FNAB-Tg was negative and the lymph nodes
were regarded as successfully treated. Samples from 10
lymph nodes did not yield diagnostic material by both
methods due to scarring successive to PEI treatment.
Observation time after initial treatment varied from 3
to 72 months (mean, 38.4).
In agreementwith others (15–18), we did not recognize
anymajor complications related to PEI treatment, and less
than 10% of patients experienced minor discomfort.
S-Tg and S-TgAb values were available from 62 pa-
tients before PEI and 60 at the end of follow-up. Before
PEI, 53 of the 62 patients had S-TgAb levels less than 10
kU/liter, whereas nine patients had positive S-TgAb mea-
surements (range, 60–1500 kU/liter). In three of the nine
patients with detectable S-TgAb before PEI, S-TgAb was
undetectable (10 kU/liter) at follow-up, indicating suc-
cessful treatment. Of the 51 patients without S-TgAb,
both initially and at the end point, 13 had undetectable
S-Tg (0.2g /liter) before PEI despitemetastatic disease.
Median S-Tg was 0.7 g/liter (range, 0.2–26 g /liter;
n  51) before PEI and less than 0.2 g/liter (range,
0.2–31 g /liter; n  51) after PEI. We did not detect
S-Tg (0.2 g/liter) or S-TgAb (10 kU/liter) in 43 pa-
tients after PEI treatment.Of the 38 patients with elevated
S-Tg levels before PEI, 30 patients had undetectable S-Tg
values (0.2 g/liter) after treatment (Fig. 2). In eight
patients, S-Tg levels were detectable (0.37–31 g/liter),
and in two patients, Tg levels were even increased at the
end of follow-up, perhaps indicating as yet unidentified
metastatic disease in the neck or elsewhere.
Discussion
A multidisciplinary approach to the diagnosis and treat-
ment of thyroid tumors is crucial. For several years, there
TABLE 2. Volume of the metastases and number of
ethanol injections performed in 92 successfully treated
metastases
No. of
injections
No. of
metastases
Metastases volume
variation (ml)
Mean met
volume (ml)
1 33 0.01–0.44 0.14
2 29 0.02–0.88 0.28
3 22 0.03–0.72 0.29
4 4 0.07–0.66 0.38
1 cystic 3.56
5 3 0.13–1.81 0.77
FIG. 1. The outcome of PEI treatment of neck lymph node metastases
(n  109).
TABLE 3. Anteroposterior, transverse, and longitudinal
diameters of the treated metastases
Diameter (mm)
Minimum Maximum Median
Pretreatment size of the
72 metastases that
disappeared after
treatment
Anteroposterior 1.8 10 3.4
Transverse 2.3 16 7.0
Longitudinal 3 27 9.2
Pretreatment size of the
20 successfully
treated metastases
Anteroposterior 2.8 16 5.0
Transverse 3.7 21 10.0
Longitudinal 4.3 27 10.5
Posttreatment size of
the 20 successfully
treated metastases
Anteroposterior 1.6 3.8 2.0
Transverse 2.5 7 4.0
Longitudinal 3 17 4.9
Pretreatment size of the
17 metastases still
under treatment
Anteroposterior 2.2 10 5.4
Transverse 2.4 14 7.2
Longitudinal 3.5 17 8.0
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have existed international and national guidelines (http://
www.legeforeningen.no/asset/45263/1/45263_1.pdf) re-
garding the management of patients with thyroid nodules
and differentiated thyroid cancer. These recommenda-
tions include evaluation and clinical and US criteria for
cytological biopsy, as well as interpretation of results and
management (6, 7). Despite this, many patients still un-
dergo diagnostic hemithyroidectomy without prior US
and FNAB, and particularly without US of neck lymph
nodes. Some of these patients turn out to have PTC NX
disease.
Due to the technical challenges and higher risk of com-
plications frequently experienced with repeated neck sur-
gery, this should be kept strictly at aminimum.Hence, the
initial preoperative staging should be in agreement with
the above-mentioned recommendations. Therefore, cen-
tral neck lymph node dissection should be performed in
conjunction with the thyroidectomy. Thus, a state-of-the-
art preoperative examination should always include a
thorough US examination of the neck performed by an
experienced radiologist using high-end US equipment.
FNAB from neck lymph nodes should always be per-
formed by an experienced cytopathologist in combination
with FNAB-Tg. Surgical treatment becomes appropriate
when using this approach, and even more patients may be
cured at the initial treatment (21).
As previously reported from our group (10), FNAB-Tg
combined with on-site cytological examination improves
the sensitivity in detecting metastatic lymph nodes. In this
study, FNAB-Tg was conclusive for malignancy in 18 of
109 cases with inconclusive FNAB. Many patients with
metastatic disease were detected after 2003 because of
more aggressive use of US during follow-up.
Controversy exists regarding prophylactic lymph node
resection in levels VI and VII when no metastatic lymph
nodes are detected before primary surgery. Irrespective of
procedure, some investigators have reported residual or
recurrentmetastatic neck lymphnodes to occur in 9–20%
of PTC patients during long-term follow-up (4, 5).
Due to the indolent biology of PTC, many researchers
claim that surgical neck exploration including resection of
benign lymph nodes detected by US is not needed
(http://cumc.columbia.edu/dept/thyroid/papillary.html)
(22). Thus “watch and wait” treatment is often recom-
mended. Lateral cervical lymphadenectomy is mainly
performed on patients with verified PTC metastases to
lateral neck compartments. Some centers favor a mod-
ified radical neck dissection followed by “berry pick-
ing” surgery when additional metastases are detected at
follow-up (23). PEI treatment of PTC metastases has
been used as an alternative to surgery (15). This ap-
proach seems to be safe, effective, fast, and without
significant complications. Whether one should perform
“berry picking” surgery subsequent to modified lymph
node dissection or “berry picking” without previous
surgery is still under debate (24–26).
PTCpatientswith undetectable S-Tg (without S-TgAb)
and negative US are considered cured. Despite undetect-
able S-Tg using a sensitive Tg assay, 13 patients without
detectable S-TgAb had metastatic neck lymph nodes.
Most of these received T4 suppression treatment, and the
patients had suppressed TSH values. Stimulated (recom-
binant human TSH or T4 withdrawal) S-Tg measurement
might have disclosed the metastatic disease. This was not
performed in these patients. The 30 patients with negative
S-TgAb and elevated S-Tg values before PEI and unde-
tectable S-Tg values at end of follow-up did not receive
recombinant human TSH stimulation. PEI treatment may
cure PTC neck lymph node metastases, but it is still not
possible to guarantee that the patient is free from meta-
static disease. Indeed, some patients included in our study
were diagnosed with recurrent lymph node metastases in
other levels after ending the study.The interval from initial
surgery to detection of neck lymph node recurrence was
highly variable, ranging from 6 to 384 months.
The increasingsensitivityofmodernUShas resulted in the
detectionofmoreandsmallermetastatic lymphnodes. Small
lymphnodesmaybebeyond surgical reach.However, inour
hospitalwehavemanaged toperformPEI treatment onmet-
astatic lymphnodes as small as 2.3mm.Whether these small
lymph node metastases are of clinical importance needs fur-
ther study. The present results are promising, indicating that
US-guided PEI treatment is cost-effectivewithoutmajor side
effects and might replace repeated surgical resections. Cen-
ters that have adopted a multimodal approach to treat PTC
FIG. 2. S-Tg values in patients with undetectable S-TgAb before PEI
treatment and at end of follow-up and S-Tg of at least 0.2 g/liter
(n  38) before PEI. Functional sensitivity of the Tg assay is 0.2 g/liter,
and S-Tg values less than 0.2 g/liter are presented as 0.1 g/liter.
Thirteen patients with S-Tg less than 0.2 g/liter both before and at
end of follow-up are not included in the figure.
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report that the crucial success depends on experience and
skill. At NRH, we have adopted a multidisciplinary ap-
proach to the management of thyroid cancer. Weekly con-
ferences are held with key members of the team, including
thyroid surgeons, radiologists, endocrinologists, oncolo-
gists, and cytopathologists.
This collaborative, supportive, multidisciplinary team
approach has been the key to our success and is a prereq-
uisite for PEI treatment of patients with PTC and neck
lymph node metastases.
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The new molecular markers DDIT3, STT3A,
ARG2 and FAM129A are not useful in
diagnosing thyroid follicular tumors
Eva Sigstad1, Elisabeth Paus2, Trine Bjøro2,3, Aasmund Berner1,3,
Krystyna Kotanska Grøholt1, Lars H Jørgensen4, Manuel Sobrinho-Simo˜es5,
Ruth Holm1 and David J Warren2
1Department of Pathology, Division of Diagnostics and Intervention, Oslo University Hospital HF,
Montebello, Norway; 2Department of Medical Biochemistry, Division of Diagnostics and Intervention,
Oslo University Hospital HF, Montebello, Norway; 3Department of Medicine, University of Oslo, Oslo,
Norway; 4Department of Thoracic Surgery, Division of Cardiovascular and Pulmonary Diseases,
Oslo University Hospital HF, Montebello, Norway and 5IPATIMUP-Institute of Molecular Pathology
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Preoperative characterization of thyroid follicular lesions is challenging. Fine-needle aspiration specimens cannot
differentiate follicular carcinomas from benign follicular neoplasias. Recently, promising markers have been
detected using modern molecular techniques. We conducted a retrospective study to confirm the usefulness of
immunohistochemical staining for the protein markers, DDIT3, STT3A (ITM1), ARG2 and FAM129A (C1orf24) in
separating benign and malignant thyroid follicular lesions. Formalin-fixed, paraffin-embedded thyroid tissue from
30 in-house cases (15 follicular carcinomas and 15 follicular adenomas), as well as 8 follicular carcinomas and 21
follicular adenomas on tissue microarray slides were stained immunohistochemically for DDIT3, STT3A, ARG2
and FAM129A expression. Control tissue consisted of thyroid parenchyma adjacent to the tumors and 11 separate
cases of normal thyroid parenchyma. All in-house cases of follicular adenomas, follicular carcinomas and
adjacent normal thyroid tissue showed positive immunostaining with anti-DDIT3 and anti-STT3A. Anti-ARG2 and
anti-FAM129A polyclonal antibodies showed positive staining in 20 and 60% of in-house follicular adenomas, and
40 and 87% of in-house follicular carcinomas, respectively. Monoclonal anti-FAM129A demonstrated positive
staining in 13 and 33% of in-house follicular adenomas and follicular carcinomas, respectively. Polyclonal anti-
DDIT3, -STT3A and -FAM129A antibodies showed positive staining in all tissue microarray slides of follicular
carcinoma and in 76, 85 and 81% of the follicular adenomas, respectively. Monoclonal anti-STT3A stained 81% of
the follicular adenoma cores. Anti-ARG2 stained positive in 13% of follicular carcinomas and 10% of follicular
adenomas on the tissue microarray slides. In conclusion, DDIT3, STT3A, ARG2 and FAM129A immunohis-
tochemistry does not appear to be useful in the diagnosis of thyroid follicular neoplasias, as they do not reliably
distinguish follicular thyroid carcinoma from follicular thyroid adenoma.
Modern Pathology (2012) 25, 537–547; doi:10.1038/modpathol.2011.188; published online 9 December 2011
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Fine-needle aspiration biopsy has become the most
widely used preoperative method to diagnose
thyroid nodules.1–3 Since it’s introduction in Europe
in the 1970s, and in the US some years later, there
has been a dramatic reduction in the need for
diagnostic hemi-thyroidectomies, whereas the yield
of thyroid carcinomas has increased.4 For papillary
carcinomas, cytology smears usually are sufficient to
make a diagnosis, due to the presence of cells with
nuclei characteristic for papillary carcinoma. In
marked contrast, in follicular neoplasias, cytological
Received 21 June 2011; revised 29 September 2011; accepted 29
September 2011; published online 9 December 2011
Correspondence: Dr E Sigstad, MD, Department of Pathology,
Division of Diagnostics and Intervention, Oslo University Hospi-
tal HF, Montebello, 0310 Oslo, Norway.
E-mail: ESP@ous-hf.no
Modern Pathology (2012) 25, 537–547
& 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 537
www.modernpathology.org
morphology cannot reliably distinguish between
benign follicular adenomas and malignant folli-
cular carcinomas.5–10 Indeed, a definite diagnosis
of follicular carcinoma requires surgical excision for
histological characterization and the examination of
multiple paraffin sections for evidence of capsular
or vascular invasion. The reported rate of malig-
nancy in follicular-patterned lesions diagnosed as
either atypical or indeterminate ranges between 20
and 30%,5,8,11–22 and many patients are operated
upon unnecessarily. The cost of these procedures is
high, both economically and in patient morbidity.
Recently, a number of promising molecular
and immunohistochemical methods have been
described, which could improve the diagnostic
accuracy of fine-needle aspiration biopsy.23–29 How-
ever, there is some inter-laboratory variability in
the sensitivity and specificities obtained with the
individual techniques as shown in the review by
Griffith et al.30 Significantly, none of the methods
has been fully validated to the extent that it is in
general use in the routine diagnostic laboratory.
In 2006, Cerutti et al31 described a test that could
discriminate between follicular carcinoma and
follicular adenoma on both paraffin sections and
cytology preparations. Their original immunohisto-
chemical method was based on the selective stain-
ing of follicular carcinoma cells by antibodies
reactive to four protein markers: DDIT3 (also known
as CHOP and GADD153), STT3A (also known as
ITM1), ARG2 and FAM129A (also known as C1orf24
and Niban). Overexpression of these proteins was
first observed using serial analysis of gene expres-
sion procedures on a single follicular carcinoma
specimen and subsequently confirmed using quan-
titative reverse-transcription PCR. The four proteins
have diverse cellular functions including nitric
oxide and polyamine metabolism (ARG2), regula-
tion of protein translation (FAM129A), regulation
of transcription as CCAAT/enhancer-binding trans-
cription factor (DDIT3), and as component of the
N-oligosaccharide transfer enzyme (STT3A). Cerutti
et al31,32 found, by using immunohistochemistry,
that the combination of the four markers distin-
guished a variety of thyroid tumors commonly
classified as indeterminate on fine-needle aspiration
biopsy, with an estimated sensitivity of 100% and
specificity of 85% for detecting malignancy.
The aim of this study was to verify the predictive
accuracy of the new biomarkers DDIT3, STT3A,
ARG2 and FAM129A in distinguishing follicular
carcinoma from follicular adenoma.
Materials and methods
Tissue Sections
Formalin-fixed, paraffin-embedded thyroid tissue
blocks were retrieved from the archive maintained
at the Department of Pathology, The Norwegian
Radium Hospital. A total of 30 cases, consisting of
15 follicular carcinomas and 15 follicular adenomas,
originally submitted for diagnostic purposes,
were included. The in-house cases have been
diagnosed histopathologically according to World
Health Organization criteria.33 Follicular neoplasias
with oncocytic differentiation, and areas containing
cells demonstrating oncocytic differentiation, were
excluded from the evaluation. In all cases, hemat-
oxylin and eosin-stained slides were reviewed to
confirm the original histopathological diagnosis.
Before embedding, the tissue specimens had been
preserved in 4% buffered formalin for variable
periods, but within the range of 2–5 days.
Two tissue microarrays containing either 80
samples from normal thyroid parenchyma (serial
TH804) or 80 thyroid cases with pathological
findings, including 8 follicular carcinomas and 21
follicular adenomas (serial TH802), were purchased
from US Biomax (Rockville, USA). The product
supplier stated that the tissues used to construct
these arrays had been preserved in neutral phos-
phate-buffered formalin for a maximum of 24h
before embedding.
Antibody Preparation
Rabbit polyclonal antisera to FAM129A (C1orf24)
and STT3A (ITM1) were generated using C-terminal
peptides as described by Cerutti et al.31 The pep-
tides were custom-synthesized and conjugated to
diphtheria toxoid (Mimotopes, Clayton, VIC, Aus-
tralia). Immunizations were performed using the
diphtheria toxoid conjugates by Eurogentec (Lie`ge,
Belgium). Monoclonal antibodies were produced by
fusion of NS0 myeloma cells with splenocytes from
BALB/c mice immunized with peptide–diphtheria
toxoid conjugates.
Antibody titration and hybridoma screening were
performed using antibody capture assays with bio-
tinylated peptides presented on streptavidin-coated
microplates (Wallac Oy, Turku, Finland). Specificity
was established using ELISA, western blotting and
125I-peptide displacement assays.
Polyclonal rabbit anti-GADD 153 (DDIT3; sc-793)
and anti-Arginase-2 (sc-20151) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Experimental animals were handled in accor-
dance with national and institutional guidelines.
125I-Peptide Displacement Assays
Competitive immunoassay tracers were produced by
incubating biotinylated peptides with an excess of
125I-labeled streptavidin. Iodination was performed
with the indirect Iodogen-method (Pierce, Rockford,
IL, USA). The test was performed by incubating
tracer and antisera (dilution 1:10 000) for 3 h in
the presence and absence of tissue homogenate.
Antibody/antigen complexes were then isolated by
the addition of sheep anti-immunoglobulin-coated
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magnetic beads (Invitrogen, Carlsbad, CA, USA).
The suspension was incubated for 1 h with shaking,
washed three times and bound tracer counted in a
g-counter.
Western Blotting
Tissue samples or cells from a follicular carcinoma
line, FTC-133 (EACC, Salisbury, UK) were homo-
genized in ice-cold RIPA buffer (TBS, 1% NP-40,
0.25% sodium deoxycholate, 0.1% SDS) containing
5mM EDTA, 1mM phenylmethylsulfonylfluoride,
0.2 mM aprotinin, 1mM leupeptin and 1 mM pep-
statin A. Following clarification, soluble protein
concentrations were determined using the BCA
method (Pierce). Between 20 and 40 mg/lane of total
protein was subjected to SDS-PAGE (Invitrogen;
Novex 4–12% gradient) and subsequently trans-
ferred onto nitrocellulose. The membranes were
blocked with 5% skimmed milk/TBS, followed by
incubation for 1h with the monoclonal (1:10 dilu-
tion of culture supernatant) or polyclonal (1:2000–
1:5000) antibodies diluted in 5% milk/TBS. Loading
controls were stained for GAPDH and a-tubulin.
Detection utilized HRP-labeled goat anti-species
immunoglobulin (1:6000 dilution poly-HRP, Pierce)
and the SuperSignal West Pico chemiluminescent
substrate (Pierce).
Immunohistochemical Staining
Immunohistochemistry was performed on 3mm
paraffin sections mounted on positively charged
slides, essentially as described by Cerutti et al.31
Tissue sections were dewaxed in xylene, followed
by rehydration using a graded ethanol series.
Endogenous peroxidase activity was suppressed by
pretreatment with 0.03% hydrogen peroxide, and
antigen retrieval was achieved using buffer AR-10
(Biogenex, San Ramon, CA, USA) in a steamer for
10min. Immunodetection was undertaken using a
Dako automated tissue-staining system (S3400;
Dako, Carpinteria, CA, USA), using EnVisionþ
HRP reagents (K4007 and K4011, Dako). Tissue
sections were exposed to the primary antibodies
for 20–22h at 4 1C. The optimal dilution of each
antibody was determined in preliminary staining
trials. Appropriate controls were prepared using
(1) non-immune polyclonal rabbit antisera or mouse
IgG1 myeloma immunoglobulin and (2) anti-
FAM129A and anti-STT3A, preabsorbed with
1mg/ml FAM129A antigen and 1mg/ml STT3A
antigen, respectively.
Two independent surgical pathologists (ES and
AaB) performed the slide evaluation. Tissue sections
were assigned to one of four groups, based on
the proportion of cells showing unequivocal stain-
ing: 0, (0%); 1, (o25%); 2, (25–50%); 3, (51–75%); 4,
(475%). The scoring system used a cutoff for
positive staining of 425%, which is in accordance
with accepted scoring methods. Arginase-2 and
STT3A staining was detected primarily in the
cytoplasm of the follicular cells, FAM129A in the
cytoplasmic membrane and the cytoplasm, whereas
DDIT3 expression was observed both in the nucleus
and the cytoplasm. For each of the in-house cases,
staining of the normal thyroid tissue adjacent to the
tumor was also evaluated. The inter-observer agree-
ment was 94% for the in-house cases and 83% for
the tissue microarray slides. Discordant cases were
reevaluated using a multi-headed microscope to
obtain a consensus. Images displayed in this article
were captured using a Leica DMLB microscope
(Type 020-519.511DMLB 100T; Leica Microsystems
GmbH, Germany) equipped with a Nikon digital
Sight DS-Fi1 camera (Nikon Corporation, Japan),
and processed using JASC Paint Shop Pro software
(Version 7.02, Corel Corporation, USA).
Statistics
The data were analyzed using the Statistical Pack-
age for the Social Sciences (SPSS), version 17.0.1
for Windows (SPSS, Chicago, IL, USA). The
Mann–Whitney U-test was used to determine
DDIT3, STT3A, ARG2 and FAM129A expression
level differences between follicular adenomas and
follicular carcinomas. A P-value of o0.05 was
considered statistically significant. Sensitivity and
specificity were calculated using standard formulae
for each of the antibodies individually, using benign
versus malignant histological diagnosis as the
standard.
Ethics
The study was approved by the Regional Committee
for Medical Research Ethics and the ‘Personvernom-
budet’ at Rikshospitalet. Informed consent for the
use of material was obtained from the patients.
Results
Production and Characterization of Antibodies
Antibodies to STT3A and FAM129A are not com-
mercially available and were produced in-house.
Rabbits were hyper-immunized with the appropriate
C-terminal peptide and antibody titers followed
by antibody-capture ELISA. After one primary
injection and three booster doses, antisera with
titers 41:10 000 were obtained. The sera were
screened by radioimmunoassay displacement ana-
lysis using follicular carcinoma, follicular adenoma
and normal tissue lysates. Sera that demonstrated
more efficient peptide displacement with follicular
carcinoma lysates compared with follicular adeno-
ma or normal cell extracts were selected (data not
shown). The specificity of the anti-FAM129A
and anti-STT3A antibodies determined by western
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blotting of total cell lysates of the FTC-133 cell line
detected proteins with the expected molecular
weight of approximately 130 and 60 kDa, respec-
tively (Figure 1).
Monoclonal antibodies were also generated using
splenocytes from mice immunized with the peptide
conjugates. Approximately, 1000 parental hybrido-
mas/peptide were screened for reactivity by anti-
body-capture assay using biotinylated peptides.
Secondary screening was undertaken by immuno-
cytochemistry using the FTC-133 cell line. Two
hybridomas were selected, producing antibodies to
FAM129A (clone E253) and STT3A (clone E239).
The specificity of the anti-FAM129A and anti-
STT3A was determined by preabsorption of the
antiserum with blocking peptides. Absorbed poly-
clonal and monoclonal anti-FAM129A antibodies
and the monoclonal anti-STT3A antibody gave
negative immunostaining. A faint immunoreaction
was observed with preabsorbed polyclonal anti-
STT3A antibody (data not shown). However, this
background was easily distinguishable from a
positive staining reaction.
Immunohistochemistry
Paraffin sections from 30 in-house cases were
screened for the expression of DDIT3, STT3A,
ARG2 and FAM129A, using a panel of polyclonal
and monoclonal antibodies (Figure 2a). Positive
staining for anti-DDIT3 and anti-STT3A was
observed in all the cases of follicular carcinoma
and follicular adenoma. The normal tissue adjacent
to the tumors was also stained. Comparable binding
was obtained with polyclonal or monoclonal anti-
STT3A antibodies. ARG2 was detected in 40% of
follicular carcinoma cases, 20% of the follicular
Figure 1 Specificity of the anti-FAM129A and anti-STT3A
antibodies as determined by western blotting. Total cell lysates
of the FTC-133 cell line were subjected to SDS-PAGE using 4–
12% gradient gels. After transfer, the nitrocellulose membranes
were stained with the primary antibody followed by a HRP-goat
anti-rabbit secondary reagent. Detection utilized a chemolumi-
nescent substrate.
Figure 2 Frequency of binding of the four antibodies to follicular
adenoma, follicular carcinoma and adjacent normal thyroid tissue
in in-house cases (a), and in follicular adenoma, follicular
carcinoma and separate cases of normal thyroid tissue in tissue
microarray cases (b). FTA¼ follicular thyroid adenoma, FTC¼ fol-
licular thyroid carcinoma, N¼normal thyroid tissue.
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adenomas and 47% of the normal thyroid tissues
adjacent to the tumors. The polyclonal antibody
to FAM129A demonstrated positive staining of
follicular cells in 87% of the follicular carcinoma
cases, 60% of the follicular adenomas and 72% of
the adjacent normal tissues. In contrast, the anti-
FAM129A monoclonal antibody stained 33% of
follicular carcinoma cases, and 13% of both the
follicular adenomas and the adjacent normal tissues.
The immunohistochemical staining with the four
antibodies of in-house follicular adenoma and
follicular carcinoma cases, and the adjacent non-
neoplastic thyroid tissue and two negative controls
is shown in Figure 3. The observed staining of
normal tissue was not due to leaking from the
adjacent follicular adenoma or follicular carcinoma,
as we found antibody binding in a panel of 11
thyroid specimens that displayed normal morpho-
logy. With this normal tissue panel, binding of
the polyclonal DDIT3, STT3A and ARG2 antibodies
was seen in all 11 individuals. Staining with the
FAM129A polyclonal antibody was found in nine
cases, whereas the monoclonal anti-FAM129A and
anti-STT3A stained seven and nine cases, respec-
tively.
In preliminary trials, we tried to ameliorate what
we thought was the ‘artifactual’ staining of follicular
adenoma and normal thyroid parenchyma, using a
range of techniques. These included alternative
antigen-retrieval buffers (citrate, Tris-Cl, citraconic
anhydride), peroxidase blocking (H2O2, H2O2/
methanol, H2O2/sodium azide), protein blocking
reagent (normal serum, casein, fish gelatine, differ-
ent BSA batches) and pre-treatment of the primary
antibodies with thiol reagents. In each case, we
failed to block the staining of follicular adenoma
and normal thyroid epithelium (data not shown).
On the tissue microarray slides (Figure 2b),
expression of DDIT3, STT3A and FAM129A was
found in all the follicular carcinoma tissue cores and
in 76, 85 and 81% follicular adenoma cores, respec-
tively. Only 13% follicular carcinoma samples and
10% of the follicular adenoma cores showed
positive staining with anti-ARG2. The tissue micro-
array slides containing normal thyroid tissue (which
did not originate from the same individuals as the
tumor cases) showed positive staining in 30, 63 and
29%, of the cores with polyclonal anti-DDIT3,
-STT3A and -FAM129A, respectively. Expression
of ARG2 was detectable in only 1% of individuals.
The monoclonal antibody to STT3A stained 46% of
the tissue cores. Immunostaining with the four
antibodies of tissue microarray cores from follicular
adenoma and follicular carcinoma cases, and sepa-
rate tissue microarray cores from normal thyroid
tissue is shown in Figure 4.
Mann–Whitney test was performed on the scoring
data from both in-house slides and tissue microarray
slides. The evaluation of difference in sum of ranks
between follicular carcinoma and follicular adeno-
ma cases revealed no significant P-values for the
in-house cases, and for the tissue microarray cases, a
P-value of 0.04 for DDIT3, and a non-significant
value for STT3A polyclonal of P¼ 0.37, for STT3A-
monoclonal of P¼ 0.24, for ARG2 of P¼ 0.28 and for
FAM129A of P¼ 0.08. Defining sensitivity as the
proportion of follicular carcinoma patients who
expressed a marker, and specificity as the propor-
tion of patients with follicular adenoma, who did
not express the marker,31 the sensitivity and speci-
ficity of staining with each of the antibodies were
calculated, and a summary of the calculated sensi-
tivity and specificity of staining with each of the
antibodies for the in-house and tissue microarray
slides is shown in Table 1a and b, respectively.
Tissue Distribution of DDIT3, STT3A, ARG2 and
FAM129A by Western Blotting
The results from immunoblotting studies are shown
in Figure 5. Tissue extracts from two carcinomas and
five adenomas were used. For one follicular carci-
noma (lane 2) and one follicular adenoma (lane 5),
tissue extracts from the non-involved lobe were also
available for testing (sample lane 3 and lane 4,
respectively). Our polyclonal and monoclonal anti-
bodies to STT3A showed high specificity and
detected a protein with the expected molecular
weight of approximately 60 kDa. Immunoblots per-
formed using the polyclonal anti-STT3A or the
corresponding monoclonal antibody showed good
concordance. With both reagents, STT3A protein
was found in all follicular carcinoma cases and in
three out of five of the follicular adenoma tissue
lysates. Low, but detectable STT3A expression was
also found in normal thyroid tissue. The polyclonal
anti-FAM129A was highly specific, detecting a
protein with an apparent Mw of about 130 kDa.
FAM129A was highly expressed in one of the
follicular carcinoma lysates, four out of five folli-
cular adenoma cases and one normal tissue extract.
In contrast to the anti-STT3A monoclonal antibody,
the anti-FAM129A monoclonal antibody performed
very poorly in western blotting and was not
characterized (data not shown). The commercial
anti-ARG2 reacted with a protein of 40 kDa with
good specificity. The protein was highly expressed
in both follicular carcinomas and three out of five
follicular adenoma lysates. Low levels of ARG2
were found in all the tissue samples. Surprisingly,
the commercial anti-DDIT3 proved highly non-
specific, showing binding to many proteins within
the 50–200 kDa range. This antibody did, however,
detect a 30 kDa protein, presumably mature DDIT3,
in one of the follicular carcinoma, but none of the
follicular adenoma tumor lysates.
Discussion
Fine-needle aspiration biopsy of the thyroid is
the most commonly used preoperative method to
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Figure 3 Immunohistochemical detection of DDIT3, STT3A, ARG2 and FAM129A in follicular adenoma and the adjacent normal thyroid
tissue (a–d;  50) and follicular carcinoma and the adjacent normal thyroid tissue (f–i; 50) in in-house cases. Negative controls are
shown in panels e and j. FTA¼ follicular thyroid adenoma, FTC¼ follicular thyroid carcinoma, N¼normal thyroid tissue.
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diagnose thyroid tumors. Although fine-needle
aspiration biopsy can reduce the number of diag-
nostic thyroidectomies by identifying clearly benign
lesions, it cannot reliably distinguish between
follicular adenoma and follicular carcinoma.
Many authors have attempted to identify molecular
markers able to predict follicular carcinoma, but
with conflicting results.30 The discordances may be
a result of the biased selection of material, the
limited number of cases examined, or the use of
very different molecular and immunohistochemical
methods. Among the most promising markers in the
recent literature are DDIT3, STT3A, ARG2 and
FAM129A that, according to Cerutti et al,31,32
reliably identify follicular carcinoma. However, the
utility of these markers has not been confirmed by
other laboratories, and they are not widely used in
diagnostic practice.
In this study, we tested the ability of immunohis-
tochemical staining for DDIT3, STT3A, ARG2 and
FAM129A, to distinguish follicular carcinoma from
follicular adenoma. Our intention was to optimize
the previously described methodology before estab-
lishing it in our diagnostic routine. Surprisingly,
and discordant to the results of Cerutti et al,31 we
found, as shown in Figure 2a, the percentage of our
in-house cases with positive staining of follicular
adenoma and follicular carcinoma to be identical
Figure 4 Immunohistochemical detection of DDIT3, STT3A, ARG2 and FAM129A in separate cases of normal thyroid tissue (a–d;
 200), follicular adenoma (e–h;  200) and follicular carcinoma (i–l; 400) on tissue microarray slides. FTA¼ follicular thyroid
adenoma, FTC¼ follicular thyroid carcinoma.
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(100%) for two of the antibodies examined (DDIT3
and STT3A), and with no significant difference
in percentage of cases of follicular adenoma and
follicular carcinoma with staining for ARG2 and
FAM129A. Furthermore, the percentage of cases
showing staining of the adjacent benign thyroid
cells was not significantly different from the
percentage of tumor cases showing staining. When
examining the tissue microarray cases (Figure 2b),
we found no significant difference in percentage
of positive follicular adenoma and follicular carci-
noma cases for three of the four antibodies examined
(STT3A, ARG2 and FAM129A), and only for DDIT3,
we did find the difference in percentage of posi-
tively stained cases of follicular adenoma and
follicular carcinoma to be of weak significance. It
is unlikely that the positive DDIT3, STT3A, ARG2
and FAM129A immunostaining of follicular adeno-
ma and normal tissues was due to differences in
methodology. We used the same antigen retrieval
and staining protocols as originally described by
Cerutti et al,31,32 and extensively optimalized the
dilutions of the primary antibodies used. Further-
more, staining was performed using the same
commercially available antibodies against ARG2
and DDIT3 utilized by Cerutti et al,31 and in-house
generated reagents were found to have high speci-
ficity to their cognate antigen in western blots.
However, the anti-FAM129A monoclonal antibody
performed poorly in immunohistochemistry and
western blotting, probably reflecting its low avidity.
We additionally stained multiple cores of follicu-
lar adenoma, follicular carcinoma and normal
thyroid parenchyma on commercially constructed
tissue microarray slides. The tissue microarray
results agreed with those obtained using wax
sections prepared in-house, and positive follicular
cell staining was found in cores containing normal
thyroid tissue. The P-value of 0.04 for DDIT3 was
found examining a small number of follicular
carcinoma (n¼ 8) and follicular adenoma (n¼ 21)
tissue microarray specimens. This finding does not
fit with the observations made of the in-house cases
demonstrating positive staining in all follicular
adenomas (n¼ 15) and all follicular carcinomas
(n¼ 15). Additionally, some quantitative differences
were seen when comparing staining with anti-ARG2
and anti-FAM129A polyclonal antibodies on fresh
sections with that on tissue microarray slides. These
were most probably related to variable degrees of
epitope degradation during the prolonged storage of
the commercial tissue microarrays.34 However, as
the tissues used to construct these arrays were fixed,
embedded and sectioned by an independent labora-
tory, they provide an appropriate control for the
variables associated with paraffin block preparation
and handling.
Because of the surprising disparity between our
immunohistochemical results and those described
previously,31,32 we determined the expression of
ARG2, FAM129A, DDIT3 and STT3A in follicular
adenoma and follicular carcinoma biopsy speci-
mens, using western blotting. In contrast to immuno-
histochemistry, western blotting can evaluate protein
expression, antibody specificity and provide a Mr of
the antibody-binding moiety and hence, a presump-
tive identity. With the exception of the commercial
anti-DDIT3 antibody, the antibody reagents demon-
strated good specificity and reacted with antigens of
the expected size in follicular adenoma and folli-
cular carcinoma lysates. In agreement with our
observations using immunohistochemistry, a sizable
proportion of the follicular adenomas displayed
significant expression of ARG2, FAM129A and
STT3A. Although anti-DDIT3 (Santa Cruz Biotech-
nology) detected a protein of the expected size in one
follicular carcinoma lysate, it displayed marked non-
specificity. In a recent paper by Haataja et al,35 three
out of seven commercially available DDIT3 antibo-
dies (including the antibody from Santa Cruz
Biotechnology that we used) gave false results by
western blotting and immunocytochemistry. This
non-specificity may explain why we observed
positive immunohistochemical staining in all freshly
cut follicular adenoma and normal tissue sections.
Although Cerutti et al31,32 used the same antibody,
they did not report on whether they characterized
each of their purchased batches.
Considering the urgent need for a technique that
can reliably discriminate between follicular carci-
noma and follicular adenoma, it is surprising that a
search of the literature indicates that we are the first
to attempt to replicate a method originally described
in 2004.32 Matsumoto et al36 observed binding of
antibodies to FAM129A to thyroid tumors with
oxyphilic cytoplasm, to oxyphilic follicular adeno-
ma and to oxyphilic variants of follicular carcinoma.
However, the authors also noted FAM129A expres-
sion in 25% of follicular non-oxyphilic follicular
adenoma and in only 50% of the non-oxyphilic
Table 1 Sensitivity and specificity of immunohistochemistry
with CI; sensitivity is defined as the proportion of follicular
carcinoma patients who expressed the marker in tumor, and
specificity as the proportion of patients with follicular adenoma,
who did not express the marker31
Sensitivity 95% CI Specificity 95% CI
(a) In-house cases
DDIT3 1.00 — 0 —
STT3Ap 1.00 — 0 —
STT3Am 1.00 — 0 —
ARG2 0.40 0.29–0.64 0.80 0.55–0.93
FAM129Ap 0.87 0.62–0.96 0.40 0.20–0.64
FAM129Am 0.33 0.15–0.58 0.87 0.62–0.96
(b) Tissue microarray cases
DDIT3 1.00 — 0.24 0.11–0.45
STT3Ap 1.00 — 0.14 0.05–0.35
STT3Am 1.00 — 0.19 0.08–0.40
ARG2 0.12 0.02–0.47 0.90 0.71–0.97
FAM129Ap 1.00 — 0.19 0.08–0.40
Abbreviation: CI, confidence intervals.
Markers in follicular thyroid neoplasms
544 E Sigstad et al
Modern Pathology (2012) 25, 537–547
follicular carcinomas. This study would therefore
also suggest that FAM129A expression discrimi-
nates poorly between follicular carcinoma and
follicular adenoma. In a recent reverse-transcription
PCR study by Patel et al37 on fine-needle aspiration
biopsy specimens, a marked downregulation of
FAM129A was found in follicular carcinoma, folli-
cular variant of papillary thyroid carcinoma and
oxyphilic follicular carcinomas, compared with
matched-normal tissue. The findings by Matsumoto
et al36 and Patel et al37 are discordant to those
presented by Cerutti et al38 in a recent validation
study, which confirmed their previous findings of
overexpression of FAM129A in all follicular carci-
nomas. Bryson et al39 found significant differences
in DDIT3 expression in a tissue panel comprising
62 follicular adenomas and 62 follicular carci-
nomas. However, they determined a sensitivity of
82% with a specificity of only 21%, which is in
agreement with our results. A study by Netea-Maier
et al40 using different gel electrophoresis found no
variance in the abundance of ARG2, FAM129A,
DDIT3 and STT3A between follicular carcinoma and
follicular adenoma. The authors concluded that the
differences in mRNA levels between follicular
carcinoma and follicular adenoma as reported by
Cerutti et al32 are of limited value, because mRNA
expression frequently does not reflect protein
abundance. Similarly, a study performing global
gene expression analysis of follicular thyroid tumors
found no difference in ARG2, DDIT3 and STT3A
expression between follicular adenoma and follicu-
lar carcinoma.41 In a meta-analysis and meta-review
by Griffith et al42 on 21 published thyroid cancer
Figure 5 Determination of ARG2, FAM129A, DDIT3 and STT3A tissue expression by western blotting. Lysates prepared from follicular
carcinoma (lane 1, 2), normal thyroid parenchyma (lane 3, 4) and follicular adenoma (lane 5–9) tissue were subjected to western blotting
as described in the legend to Figure 1. Normal tissues 2 and 3 were obtained from the uninvolved thyroid lobe of patent 2 and 5,
respectively. *Sample not run due to insufficient lysate.
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gene expression studies, including the study by
Cerutti et al,32 ARG2, DDIT3, STT3A and FAM129A
are not among the 39 markers with overlap of three
or more candidate markers for the cancer versus
non-cancer group.
Our insight into gene expression in tumor cells
has increased rapidly with the help of DNA and
protein microarray analyses. However, the interpre-
tation of the acquired data is challenging, and is
subject to several potential pitfalls. The importance
of a close collaboration between the investigators
performing the microarrays and experienced biosta-
tisticians is crucial.43 Morphology is still the gold
standard when evaluating thyroid neoplasms.
Indeed, for the majority of thyroid tumors, the
identification of ‘‘abnormal’’ tissue on histological
preparations will probably long remain a prerequi-
site before performing immunohistochemistry or
molecular analysis. Unfortunately, as this study
demonstrates, the search for the ideal marker
capable of discriminating between follicular carci-
noma and follicular adenoma must continue.
In conclusion, in this study, we determined
whether screening for the expression of the biomar-
kers DDIT3, STT3A, ARG2 and FAM129A, is able to
distinguish between follicular thyroid adenoma and
carcinoma. Regrettably, using both immunohisto-
chemistry and western blotting, we demonstrate that
these markers are not useful for this purpose. The
reasons for the discordance between our results and
those of Cerutti et al31,32 are, at present, and despite
considerable focus on quality assurance of all steps,
unknown. In our hands, the method is not usable for
screening thyroid nodules in patient populations.
The failure of this study to replicate a previously
published method highlights the need for extensive
validation studies to determine if a previously
advanced classifier has clinical utility in an inde-
pendent set of cases.
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